drTarget portfolio target-disease associations for respiratory diseases DrTarget’s AI-Powered Indication Expansion for Respiratory Diseases

DrTarget’s AI-Powered Insights for Respiratory Diseases

DrTarget leverages advanced AI and machine learning to map target-disease associations for respiratory diseases, utilizing data from ChEMBL, Open Targets and PubChem. Our computational models uncover novel drug targets and therapeutic opportunities for conditions such as:

✔ Chronic Obstructive Pulmonary Disease (COPD)
✔ Asthma
✔ Pulmonary Fibrosis
✔ Acute Respiratory Distress Syndrome (ARDS)
✔ Cystic Fibrosis

By integrating virtual screening, drug repurposing strategies, and pathway analysis, we identify key molecular mechanisms involved in inflammation, fibrosis, and immune dysregulation. This approach supports the development of next-generation respiratory treatments, bridging the gap between AI-driven predictions and clinical research.

Target-disease associations for respiratory diseases.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	chronic obstructive pulmonary disease	targetBased	343786	1253	0.380365631777865	668
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	chronic obstructive pulmonary disease	targetBased	296501	2737	0.380365631777865	668
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	chronic obstructive pulmonary disease	targetBased	394050	3624	0.568331115960879	53
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	chronic obstructive pulmonary disease	targetBased	335239	991	0.604623538113648	14
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	chronic obstructive pulmonary disease	targetBased	335239	695	0.604623538113648	14
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	chronic obstructive pulmonary disease	targetBased	405130	6428	0.429838963413524	38
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	chronic obstructive pulmonary disease	targetBased	373462	23	0.429838963413524	38
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	chronic obstructive pulmonary disease	targetBased	405130	6428	0.429838963413524	38
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	chronic obstructive pulmonary disease	targetBased	75924	1804	0.377102675649982	33
Novel sEH inhibitors for the therapeutic treatment of hypertension and inflammation	sEH_inhibitors	chronic obstructive pulmonary disease	targetBased	90640	310	0.305188045034196	36
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	chronic obstructive pulmonary disease	targetBased	359207	1189	0.662832074953336	287
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	chronic obstructive pulmonary disease	targetBased	63676	1938	0.662832074953336	287
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	chronic obstructive pulmonary disease	targetBased	359207	316	0.662832074953336	287
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	chronic obstructive pulmonary disease	targetBased	63656	2179	0.662832074953336	287
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	chronic obstructive pulmonary disease	targetBased	359207	4555	0.662832074953336	287
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	chronic obstructive pulmonary disease	targetBased	339297	1446	0.693504127735036	1633
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	chronic obstructive pulmonary disease	targetBased	31324	362	0.483585160636221	8
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	chronic obstructive pulmonary disease	targetBased	363803	1450	0.65800497078166	173
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	chronic obstructive pulmonary disease	targetBased	363803	2629	0.65800497078166	173
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	chronic obstructive pulmonary disease	targetBased	363803	502	0.65800497078166	173
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	chronic obstructive pulmonary disease	targetBased	363803	698	0.65800497078166	173
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	chronic obstructive pulmonary disease	targetBased	363803	2133	0.65800497078166	173
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	chronic obstructive pulmonary disease	targetBased	363803	1081	0.65800497078166	173
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	emphysema	targetBased	339297	1446	0.660629027927607	50
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	respiratory system disease	targetBased	343786	1253	0.604308638464213	6538
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	respiratory system disease	targetBased	296501	2737	0.604308638464213	6538
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	respiratory system disease	pathwayBased	64908	979	0.378130766497915	53
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	respiratory system disease	pathwayBased	64908	278	0.378130766497915	53
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	respiratory system disease	targetBased	336894	489	0.284151958368056	417
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	respiratory system disease	targetBased	335239	991	0.56428276068475	66
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	respiratory system disease	targetBased	335239	695	0.56428276068475	66
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	respiratory system disease	targetBased	75924	1804	0.474780977159598	114
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	respiratory system disease	targetBased	360873	7438	0.283980323863213	376
qHTS of Nrf2 Activators	Nrf2 activators	respiratory system disease	pathwayBased	403871	1243	0.283980323863213	376
qHTS assay for re-activators of p53 using a Luc reporter	TP53	respiratory system disease	pathwayBased	321427	201	0.321938078914482	3704
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory system disease	targetBased	54509	528	0.321938078914482	3704
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory system disease	targetBased	54513	338	0.321938078914482	3704
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory system disease	targetBased	125394	1890	0.321938078914482	3704
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory system disease	targetBased	124022	1156	0.321938078914482	3704
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	respiratory system disease	targetBased	356517	1139	0.251138433718564	2504
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	respiratory system disease	pathwayBased	7671	874	0.314260976118431	47
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	respiratory system disease	targetBased	304060	10600	0.314260976118431	47
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	respiratory system disease	pathwayBased	305439	16717	0.314260976118431	47
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	respiratory system disease	targetBased	322361	619	0.257875014611517	306
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	respiratory system disease	targetBased	215667	993	0.335425172738696	62
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	respiratory system disease	targetBased	218234	1620	0.335425172738696	62
HTS of Smad transcription factor inhibitors	SMAD3	respiratory system disease	targetBased	88033	251	0.557918542338559	323
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	respiratory system disease	targetBased	193542	587	0.273653431359506	161
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	respiratory system disease	targetBased	339297	1446	0.256338312805818	1242
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	respiratory system disease	targetBased	305610	3794	0.503522045856373	15
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	respiratory system disease	targetBased	339674	2841	0.57220528861961	170
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	pulmonary arterial hypertension	targetBased	359207	1432	0.441191064250345	32
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	pulmonary arterial hypertension	targetBased	339297	1446	0.499611061442305	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pulmonary arterial hypertension	targetBased	339674	2841	0.614624258622599	235
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	lung disease	targetBased	343786	1253	0.293629093141759	713
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	lung disease	targetBased	296501	2737	0.293629093141759	713
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lung disease	targetBased	335239	991	0.581433542946119	43
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	lung disease	targetBased	335239	695	0.581433542946119	43
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	lung disease	targetBased	360873	7438	0.27678487273454	331
qHTS of Nrf2 Activators	Nrf2 activators	lung disease	pathwayBased	403871	1243	0.27678487273454	331
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lung disease	pathwayBased	321427	201	0.304660573591682	3175
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung disease	targetBased	54509	528	0.304660573591682	3175
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung disease	targetBased	54513	338	0.304660573591682	3175
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung disease	targetBased	125394	1890	0.304660573591682	3175
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lung disease	targetBased	124022	1156	0.304660573591682	3175
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	lung disease	targetBased	356517	1139	0.250912353985337	2111
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lung disease	targetBased	322361	619	0.254422390952243	211
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	lung disease	targetBased	339297	1446	0.468166592588468	641
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	lung disease	targetBased	305610	3794	0.565673039075681	12
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	lung disease	targetBased	339674	2841	0.552280221607979	15
HCS assay for microtubule stabilizers	TUBB	lung disease	targetBased	195821	1625	0.418360168557414	938
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	lung disease	targetBased	343468	734	0.407391059493617	117
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	interstitial lung disease	targetBased	335239	991	0.430844594398808	7
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	interstitial lung disease	targetBased	335239	695	0.430844594398808	7
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)	PADI4	interstitial lung disease	targetBased	326022	1334	0.542477327565812	37
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	forced expiratory volume	targetBased	86095	1442	0.484277020001765	8
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	forced expiratory volume	targetBased	86095	1151	0.484277020001765	8
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	forced expiratory volume	targetBased	343467	1710	0.42621457572027	11
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	forced expiratory volume	targetBased	31324	362	0.512931148576678	8
qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	forced expiratory volume	targetBased	330109	4174	0.346686856422428	6
qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1	ATAD5_inhibitors	forced expiratory volume	targetBased	330107	7652	0.346686856422428	6
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	forced expiratory volume	targetBased	331671	10022	0.29396911574075	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	common cold	targetBased	316642	617	0.660607902407363	99
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	chronic bronchitis	targetBased	343786	1253	0.444115844834956	80
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	chronic bronchitis	targetBased	296501	2737	0.444115844834956	80
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	chronic bronchitis	targetBased	359207	1189	0.60466648961276	9
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	chronic bronchitis	targetBased	63676	1938	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	chronic bronchitis	targetBased	359207	316	0.60466648961276	9
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	chronic bronchitis	targetBased	63656	2179	0.60466648961276	9
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	chronic bronchitis	targetBased	359207	4555	0.60466648961276	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	chronic bronchitis	targetBased	339297	1446	0.650991429284571	41
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	lower respiratory tract disease	pathwayBased	64908	979	0.372411203974402	38
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	lower respiratory tract disease	pathwayBased	64908	278	0.372411203974402	38
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	lower respiratory tract disease	targetBased	75924	1804	0.385958051745479	75
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	lower respiratory tract disease	targetBased	325630	216	0.401213839254712	124
HTS of Smad transcription factor inhibitors	SMAD3	lower respiratory tract disease	targetBased	88033	251	0.477251917514669	247
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	rhinitis	targetBased	394050	3624	0.363313472569608	11
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	rhinitis	targetBased	316642	617	0.558652137696846	31
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Status Asthmaticus	targetBased	339297	1446	0.564750926143729	15
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	bronchitis	targetBased	339297	1446	0.610966153644012	26
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	respiratory failure	targetBased	339297	1446	0.253522525727199	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	respiratory failure	targetBased	305610	3794	0.430510676254091	6
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	respiratory failure	targetBased	339674	2841	0.430510676254091	6
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	respiratory depression	targetBased	290355	265	0.410642462581269	35
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	respiratory depression	targetBased	335239	991	0.554945878660219	261
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	respiratory depression	targetBased	335239	695	0.554945878660219	261
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	atopic asthma	targetBased	75924	1804	0.325873607329096	11
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	atopic asthma	targetBased	339297	1446	0.40531047015466	11
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	chronic lung disease	targetBased	343786	1253	0.284310446262139	534
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	chronic lung disease	targetBased	296501	2737	0.284310446262139	534
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	acute respiratory distress syndrome	targetBased	335239	991	0.59062134940304	12
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	acute respiratory distress syndrome	targetBased	335239	695	0.59062134940304	12
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute respiratory distress syndrome	targetBased	339297	1446	0.574515955536212	10
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	acute respiratory distress syndrome	targetBased	305610	3794	0.569651415559999	9
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	acute respiratory distress syndrome	targetBased	339674	2841	0.569651415559999	9
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	acute respiratory distress syndrome	targetBased	343468	734	0.370796899415496	8
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	adult onset asthma	targetBased	75924	1804	0.469663335548261	6
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	bronchial disease	targetBased	343786	1253	0.27824319097566	409
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	bronchial disease	targetBased	296501	2737	0.27824319097566	409
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	adult onset asthma	targetBased	215667	993	0.280819212097695	6
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	adult onset asthma	targetBased	218234	1620	0.280819212097695	6
HTS of Smad transcription factor inhibitors	SMAD3	adult onset asthma	targetBased	88033	251	0.487600993685792	6
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Nasal congestion	targetBased	324747	813	0.619285523949174	12
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Nasal congestion	targetBased	339297	1446	0.593396752228544	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Respiratory insufficiency	targetBased	335239	991	0.560128487470336	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Respiratory insufficiency	targetBased	335239	695	0.560128487470336	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	Apnea	targetBased	339674	2841	0.507493179017352	6
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Bronchiectasis	targetBased	343786	1253	0.523752880488721	210
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Bronchiectasis	targetBased	296501	2737	0.523752880488721	210
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Bronchiectasis	pathwayBased	195980	5134	0.377339646715432	15
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Bronchiectasis	targetBased	195980	695	0.377339646715432	15
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Bronchiectasis	targetBased	339297	1446	0.540316289148883	6
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Cough	targetBased	290355	265	0.516525873530802	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cough	targetBased	335239	991	0.581380049750662	12
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Cough	targetBased	335239	695	0.581380049750662	12
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Bronchiolitis	targetBased	339297	1446	0.600348864114163	17
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Airway obstruction	targetBased	339297	1446	0.66063970750587	92
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	acute respiratory failure	targetBased	335239	991	0.257854355545723	7
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	acute respiratory failure	targetBased	335239	695	0.257854355545723	7
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute respiratory failure	targetBased	339297	1446	0.469631009806937	10
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	pharyngitis	targetBased	316642	617	0.65652647227677	59
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	bronchiectasis	targetBased	343786	1253	0.604141117825392	510
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	bronchiectasis	targetBased	296501	2737	0.604141117825392	510
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	upper respiratory tract disorder	pathwayBased	193265	3100	0.351531774174647	437
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	upper respiratory tract disorder	pathwayBased	359244	3094	0.351531774174647	437
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	upper respiratory tract disorder	targetBased	75924	1804	0.355259888309021	39
HTS of Smad transcription factor inhibitors	SMAD3	upper respiratory tract disorder	targetBased	88033	251	0.498401279501692	44
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	asthma	pathwayBased	64908	979	0.500776184626738	37
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	asthma	pathwayBased	64908	278	0.500776184626738	37
qHTS for Inhibitors of Polymerase Iota	POLI	asthma	targetBased	386063	3989	0.340473522407503	10
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	asthma	pathwayBased	193265	3100	0.298390830613076	55
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	asthma	pathwayBased	359244	3094	0.298390830613076	55
qHTS of IL-2 Activators	IL2	asthma	targetBased	364617	238	0.254125861322171	53
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	asthma	targetBased	394050	3624	0.631902928952217	41
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	asthma	targetBased	75924	1804	0.558542526045273	104
Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE)	IDE	asthma	targetBased	335239	245	0.280786565585466	11
Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)	IDE	asthma	targetBased	324747	1316	0.280786565585466	11
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	asthma	pathwayBased	362051	17187	0.294370986515124	39
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	asthma	pathwayBased	7671	874	0.348234913278362	8
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	asthma	targetBased	304060	10600	0.348234913278362	8
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	asthma	pathwayBased	305439	16717	0.348234913278362	8
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	asthma	targetBased	215667	993	0.317840642239847	23
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	asthma	targetBased	218234	1620	0.317840642239847	23
qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase)	ALOX15_inhibitors	asthma	targetBased	73174	1034	0.391291961194972	7
HTS of Smad transcription factor inhibitors	SMAD3	asthma	targetBased	88033	251	0.571802370116916	77
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	asthma	targetBased	292323	1836	0.520166802217511	12
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	asthma	targetBased	359207	1189	0.59019417757692	24
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	asthma	targetBased	63676	1938	0.59019417757692	24
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	asthma	targetBased	359207	316	0.59019417757692	24
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	asthma	targetBased	63656	2179	0.59019417757692	24
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	asthma	targetBased	359207	4555	0.59019417757692	24
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	asthma	targetBased	339297	1446	0.672561601153222	1631
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	asthma	targetBased	363803	1450	0.585061000347239	16
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	asthma	targetBased	363803	2629	0.585061000347239	16
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	asthma	targetBased	363803	502	0.585061000347239	16
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	asthma	targetBased	363803	698	0.585061000347239	16
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	asthma	targetBased	363803	2133	0.585061000347239	16
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	asthma	targetBased	363803	1081	0.585061000347239	16
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	childhood onset asthma	pathwayBased	64908	979	0.417970276977229	6
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	childhood onset asthma	pathwayBased	64908	278	0.417970276977229	6
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	childhood onset asthma	targetBased	75924	1804	0.48807545126411	27
HTS of Smad transcription factor inhibitors	SMAD3	childhood onset asthma	targetBased	88033	251	0.528510372937196	12
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	asthma	targetBased	325630	216	0.491425618907316	24
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	bronchiectasis with or without elevated sweat chloride 1	targetBased	343786	1253	0.760900509374716	894
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	bronchiectasis with or without elevated sweat chloride 1	targetBased	296501	2737	0.760900509374716	894
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	cystic fibrosis	targetBased	343786	1253	0.996125989381412	17187
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	cystic fibrosis	targetBased	296501	2737	0.996125989381412	17187
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	cystic fibrosis	targetBased	86095	1442	0.425481493464507	15
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	cystic fibrosis	targetBased	86095	1151	0.425481493464507	15
qHTS for Inhibitors of TGF-b	TGFB1	cystic fibrosis	pathwayBased	403345	4970	0.480569637759883	159
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	cystic fibrosis	targetBased	394050	3624	0.52252841740507	12
Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition	VCP	cystic fibrosis	targetBased	217959	923	0.509487978883046	12
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	heritable pulmonary arterial hypertension	targetBased	339674	2841	0.550807387763399	108
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	primary ciliary dyskinesia	pathwayBased	193265	3100	0.371648354277948	20
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	primary ciliary dyskinesia	pathwayBased	359244	3094	0.371648354277948	20
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	idiopathic bronchiectasis	targetBased	343786	1253	0.281231933265529	310
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	idiopathic bronchiectasis	targetBased	296501	2737	0.281231933265529	310
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute bronchiolitis	targetBased	339297	1446	0.51000069558534	6
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	respiratory system disease	targetBased	217959	2390	0.267305170653675	225
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	respiratory system disease	targetBased	344733	7043	0.262064681773521	163
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	respiratory system disease	targetBased	71016	346	0.285387508742238	105
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	respiratory system disease	targetBased	46715	2829	0.278969248284901	179
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	lung disease	targetBased	46715	2829	0.278306948306896	167
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	lung disease	targetBased	336894	489	0.260711484934816	385
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	lung disease	targetBased	344733	7043	0.258042393556257	150
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	lung disease	targetBased	193542	587	0.266912019273606	136
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	lower respiratory tract disease	targetBased	343786	1253	0.280987278872548	635
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	lower respiratory tract disease	targetBased	296501	2737	0.280987278872548	635
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	lower respiratory tract disease	targetBased	336894	489	0.26180507540306	387
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	lower respiratory tract disease	targetBased	46715	2829	0.278407482230726	170
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	lower respiratory tract disease	targetBased	344733	7043	0.259526998877001	153
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	lower respiratory tract disease	targetBased	360873	7438	0.264884661357852	328
qHTS of Nrf2 Activators	Nrf2 activators	lower respiratory tract disease	pathwayBased	403871	1243	0.264884661357852	328
qHTS assay for re-activators of p53 using a Luc reporter	TP53	lower respiratory tract disease	pathwayBased	321427	201	0.302669451002373	3281
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lower respiratory tract disease	targetBased	54509	528	0.302669451002373	3281
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lower respiratory tract disease	targetBased	54513	338	0.302669451002373	3281
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lower respiratory tract disease	targetBased	125394	1890	0.302669451002373	3281
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	lower respiratory tract disease	targetBased	124022	1156	0.302669451002373	3281
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	lower respiratory tract disease	targetBased	322361	619	0.254278231517585	218
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	lower respiratory tract disease	targetBased	71016	346	0.269982248718816	69
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	lower respiratory tract disease	targetBased	193542	587	0.268537199086942	138
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	pleural disorder	targetBased	71016	346	0.253869843213445	53
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	tracheal disorder	targetBased	343786	1253	0.27791994371107	497
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	tracheal disorder	targetBased	296501	2737	0.27791994371107	497
qHTS assay for re-activators of p53 using a Luc reporter	TP53	nasopharyngeal disorder	pathwayBased	321427	201	0.270001228515148	33
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal disorder	targetBased	54509	528	0.270001228515148	33
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal disorder	targetBased	54513	338	0.270001228515148	33
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal disorder	targetBased	125394	1890	0.270001228515148	33
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	nasopharyngeal disorder	targetBased	124022	1156	0.270001228515148	33
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	upper respiratory tract disorder	targetBased	343786	1253	0.277921987826351	519
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	upper respiratory tract disorder	targetBased	296501	2737	0.277921987826351	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	upper respiratory tract disorder	pathwayBased	321427	201	0.283124799711998	333
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper respiratory tract disorder	targetBased	54509	528	0.283124799711998	333
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper respiratory tract disorder	targetBased	54513	338	0.283124799711998	333
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper respiratory tract disorder	targetBased	125394	1890	0.283124799711998	333
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper respiratory tract disorder	targetBased	124022	1156	0.283124799711998	333
qHTS assay for re-activators of p53 using a Luc reporter	TP53	disorder of pharynx	pathwayBased	321427	201	0.277382427343331	95
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of pharynx	targetBased	54509	528	0.277382427343331	95
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of pharynx	targetBased	54513	338	0.277382427343331	95
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of pharynx	targetBased	125394	1890	0.277382427343331	95
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of pharynx	targetBased	124022	1156	0.277382427343331	95
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	respiratory or thoracic disease	targetBased	343786	1253	0.332808758011083	6518
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	respiratory or thoracic disease	targetBased	296501	2737	0.332808758011083	6518
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	respiratory or thoracic disease	targetBased	336894	489	0.274632786857521	413
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	respiratory or thoracic disease	targetBased	217959	2390	0.267305170653675	225
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	respiratory or thoracic disease	targetBased	46715	2829	0.278969248284901	179
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	respiratory or thoracic disease	targetBased	360873	7438	0.270135376355121	370
qHTS of Nrf2 Activators	Nrf2 activators	respiratory or thoracic disease	pathwayBased	403871	1243	0.270135376355121	370
qHTS assay for re-activators of p53 using a Luc reporter	TP53	respiratory or thoracic disease	pathwayBased	321427	201	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory or thoracic disease	targetBased	54509	528	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory or thoracic disease	targetBased	54513	338	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory or thoracic disease	targetBased	125394	1890	0.31595798980029	3696
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	respiratory or thoracic disease	targetBased	124022	1156	0.31595798980029	3696
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	respiratory or thoracic disease	targetBased	322361	619	0.256252172428189	305
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	respiratory or thoracic disease	targetBased	71016	346	0.285387508742238	105
HTS of Smad transcription factor inhibitors	SMAD3	respiratory or thoracic disease	targetBased	88033	251	0.262004337131526	317
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	respiratory or thoracic disease	targetBased	193542	587	0.272030589176179	160
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	respiratory or thoracic disease	targetBased	339674	2841	0.30173159139841	169
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	respiratory or thoracic disease	targetBased	344733	7043	0.262064681773521	163

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROPRANOLOL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01070225	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute respiratory distress syndrome	ISOPROTERENOL	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05658692	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ISOPROTERENOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AB02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ISOPROTERENOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CB01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ISOPROTERENOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CB51	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Apnea	BUSPIRONE	targetBased	3	Terminated	01/09/2008	https://clinicaltrials.gov/study/NCT00746954	0.7	GoF	protect	Patient recruitment and Funding inadequate to finish trial
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Apnea	BUSPIRONE	targetBased	3	Terminated	01/09/2008	https://clinicaltrials.gov/study/NCT00746954	0.7	GoF	protect	Patient recruitment and Funding inadequate to finish trial
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	Cough	THALIDOMIDE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00600028	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	MORPHINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01236495	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	MORPHINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01236495	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	4	Active, not recruiting	15/11/2019	https://clinicaltrials.gov/study/NCT03834363	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	4	Active, not recruiting	15/11/2019	https://clinicaltrials.gov/study/NCT03834363	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	4	Completed	16/11/2016	https://clinicaltrials.gov/study/NCT02429050	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	4	Completed	16/11/2016	https://clinicaltrials.gov/study/NCT02429050	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	3	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT01718496	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	MORPHINE	targetBased	3	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT01718496	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulmonary edema	MORPHINE	targetBased	4	Terminated	08/04/2017	https://clinicaltrials.gov/study/NCT02856698	0.5	GoF	protect	The study was stopped because of the adverse events
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulmonary edema	MORPHINE	targetBased	4	Terminated	08/04/2017	https://clinicaltrials.gov/study/NCT02856698	0.5	GoF	protect	The study was stopped because of the adverse events
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	CODEINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	CODEINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA04	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cough	CODEINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA04	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	NALOXONE	targetBased	4	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02885948	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	NALOXONE	targetBased	4	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02885948	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	respiratory depression	NALOXONE	targetBased	4	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02885948	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	lung disease	COLCHICINE	targetBased	3	Withdrawn	01/09/1993	https://clinicaltrials.gov/study/NCT00000577	0.7	LoF	protect	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	asthma	COLCHICINE	targetBased	3	Withdrawn	01/09/1993	https://clinicaltrials.gov/study/NCT00000577	0.7	LoF	protect	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008c5055-4ae3-498f-a7bf-5bd00f738c6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2354204f-0d47-4232-8ca6-f74913847ac7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=720366f1-f2d1-6dd6-7bf1-9fdd9378b073	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f653f79-63b9-4c2b-8fe6-d7bb29d84636	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56728a9d-ada8-4784-898a-21d639606358	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47c61858-72ce-409b-a3af-a63620cf7d13	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=328fd31e-e715-4aa5-a0a0-ebe64f21d8d6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9eee551c-0bf8-4351-a0f2-68af9fc51eb7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0b36e4d-3667-58f6-e053-2a95a90afad7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe37f2e-cf13-451d-8988-e96a5712e359	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	3	Withdrawn	01/04/2016	https://clinicaltrials.gov/study/NCT01938144	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3658b70c-9abf-4c7e-be58-6bcc0d7c78de	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135b2e99-92d1-4312-8ff9-ca44368f6874	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a3f498d-445f-410b-818f-9f119bd6c492	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e902e339-b5bc-4c5d-9861-662f739ccb12	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a562b5-501e-49ef-8c9d-27d07e86ea97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=478e8edb-ca2c-5f76-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01686646	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=251f2782-e7ae-11e1-aff1-0800200c9a66	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28f41696-7d67-436e-aa33-86d8ba82efd7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=842706f9-eedf-1783-49ed-e6b7ae7d650e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11c28c6c-d2f0-4092-8ef1-4262b17be50e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8c6d31-0dec-4353-8094-f4abf92f644d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=182a105b-bd49-42b5-b4e0-46e5ec0197e3	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d3a6994-86f4-3a9a-e053-2991aa0a8a6c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60183922-bfd3-4377-884a-51b2f0a4c93a	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f0f6488-0366-4bdf-ad49-cdbdced9d0c9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e119fafe-9d50-4555-9bd9-389e4a1e2718	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294a5ed5-8ae9-48cb-a6ec-094729ba40b2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fd31f1c-0fab-4fd2-a0f1-56ade1f013f0	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cdbe0b3a-ced3-465c-92a1-a526bbd07f09	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b995a0b2-898d-4a8f-b44f-097ae54e0ba5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27312ee4-d1f4-4a95-9c45-91fa5a01f5ba	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028062ea-5072-45c1-80f0-e291d94b4dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	3	Not yet recruiting	20/09/2024	https://clinicaltrials.gov/study/NCT05070650	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd759f58-5912-40d5-a5de-632df3e61a79	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d21e453-db6d-4c8a-b6f4-8ede319d0c95	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84e7be8f-2785-45ef-9c44-de05394fcd99	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8b253c9c-007e-4109-9d8d-2f318d522420	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dad63da3-cd1f-42a8-93d5-44b39aae1268	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e4219a-a4ef-f090-f6a4-2fd2e213d397	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a8f798e-cd54-4b39-b8d4-28227ebbaeb5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1241e896-be03-48f5-b825-b520189e2b3b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15361568-74a9-4dc2-a27a-4e1298c86b51	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc11b349-9e1c-4e3c-80d2-07749a67391e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad788820-1320-4e21-9b9f-82dc0e454335	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e944d5-3473-4d8c-8df4-2ffc7474e9fa	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01466348	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b705a2-2312-46f8-871b-09df2bbff1e6	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd372e00-c378-43bd-974c-f44f8adddb57	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9c3c12b-4efa-4ec4-a156-c403aff81753	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc4d100b-eaa9-4e46-a27a-74094aa11d0f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b37b786e-0cce-419d-94ed-3b64a1eb1201	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f172d58-4050-424b-9743-130d8e618fe8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf30c75-e867-4a2f-a481-702d7aa96c23	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c7dbac3-dd9e-d03a-1303-3d2a207c751b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97c99b40-bcd9-710b-e053-2a95a90a10a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2307f52c-8ea3-43b4-9b9f-bd60ac939f24	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bfacd95-3300-46a3-8699-1dcca035b6df	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd7b5ba3-652a-443f-b0b9-17abda148e67	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad6408ff-079b-4757-e053-2995a90a53eb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=affddef4-c724-4bf6-8608-6eeffa38d684	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	common cold	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7486dadf-cd61-478c-8c0e-ad14f7e7ac6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=523561fb-f6a7-4cde-9be2-bba02e60e208	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2354204f-0d47-4232-8ca6-f74913847ac7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56728a9d-ada8-4784-898a-21d639606358	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba17b25c-fc4d-4673-82a3-49ab07cab1d9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7486dadf-cd61-478c-8c0e-ad14f7e7ac6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008c5055-4ae3-498f-a7bf-5bd00f738c6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	3	Completed	27/09/2011	https://clinicaltrials.gov/study/NCT01453400	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f466c660-69eb-4581-81ff-1499fa421d8b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=135b2e99-92d1-4312-8ff9-ca44368f6874	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5278a128-41ec-4494-e054-00144ff8d46c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94fdab-27ea-4c0f-a91c-735ce697304b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4	Completed	01/12/2017	https://clinicaltrials.gov/study/NCT03768882	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11c28c6c-d2f0-4092-8ef1-4262b17be50e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e8c6d31-0dec-4353-8094-f4abf92f644d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad6408ff-079b-4757-e053-2995a90a53eb	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e32881f5-2bb5-4756-aa86-a09473ab590b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a8f798e-cd54-4b39-b8d4-28227ebbaeb5	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15361568-74a9-4dc2-a27a-4e1298c86b51	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4ba51b8-e86f-4227-e053-2995a90a853e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=720366f1-f2d1-6dd6-7bf1-9fdd9378b073	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f631f45-06e4-4860-abb7-1e1b1e146035	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=491ad8a0-1d6b-457a-982a-e68b1def7b55	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=028062ea-5072-45c1-80f0-e291d94b4dbe	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4cde7fc-d86a-1418-e053-2a95a90aed25	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad788820-1320-4e21-9b9f-82dc0e454335	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853012b8-d3b7-78d3-e053-2a91aa0ab0f2	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f0f6488-0366-4bdf-ad49-cdbdced9d0c9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe37f2e-cf13-451d-8988-e96a5712e359	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01048866	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1241e896-be03-48f5-b825-b520189e2b3b	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05e944d5-3473-4d8c-8df4-2ffc7474e9fa	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7cf7c5d-5c9a-4201-9e30-1cd616071855	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd3f2ccc-ae74-4000-888c-7f25e41dbc3d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=763a5334-a741-4678-9947-603776622450	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24a562b5-501e-49ef-8c9d-27d07e86ea97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6dddc7c-370f-447b-b24e-8cc68b352c4c	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e119fafe-9d50-4555-9bd9-389e4a1e2718	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c98b5bd-be18-4334-b6c7-bf51cd8ccb00	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pharyngitis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45276fb7-80c0-4949-b59c-0970e156c13d	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	FENTANYL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00696137	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	FENTANYL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00696137	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	FENTANYL	targetBased	3	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT06185127	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	FENTANYL	targetBased	3	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT06185127	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03405090	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03405090	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL	targetBased	4	Active, not recruiting	15/11/2019	https://clinicaltrials.gov/study/NCT03834363	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL	targetBased	4	Active, not recruiting	15/11/2019	https://clinicaltrials.gov/study/NCT03834363	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	FENTANYL	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01368809	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	FENTANYL	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01368809	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	FENTANYL	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05024799	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	FENTANYL	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05024799	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory system disease	FENTANYL	targetBased	4	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05856136	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory system disease	FENTANYL	targetBased	4	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05856136	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial lung disease	FENTANYL	targetBased	3	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03018756	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial lung disease	FENTANYL	targetBased	3	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03018756	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	NEBIVOLOL	targetBased	4	Recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT04845061	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	OXYCODONE	targetBased	4	Completed	10/10/2022	https://clinicaltrials.gov/study/NCT05598905	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory depression	OXYCODONE	targetBased	4	Completed	10/10/2022	https://clinicaltrials.gov/study/NCT05598905	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	SUFENTANIL	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	SUFENTANIL	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute respiratory distress syndrome	EPINEPHRINE	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05658692	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal congestion	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R01AA14	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AA01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	EPINEPHRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AK01	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulmonary arterial hypertension	EPINEPHRINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT05439460	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01705964	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e609bab7-c671-424d-bd9d-ced0affa0b4d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de6a969a-7e0f-4e5f-8d12-de5c7129d39c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=daa651e5-40e1-4e87-9775-3f7cc44dff32	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3d99dc-cb35-4331-96cd-fedb95b96750	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a41b3e0c-8f43-49a5-90ea-0509e5fc18e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d5af590-59f6-4f34-95ff-226a2996f985	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03ce427-2dfa-460c-a1a9-c659d7a35b67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b3e639-cd9d-46b0-8505-86b0214cb20b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d785beac-3f68-4df1-926f-34da6773f295	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01357642	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c07b20c-d222-4b42-87b8-9667705a2945	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460511	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da3009a0-9eed-4254-90f9-b4b024073828	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0babff47-11ed-47b6-a57d-502ca3c86973	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d391a-0525-4172-add9-5cb45e0c5d67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01737905	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01476904	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5ede55-10de-491e-a73f-17a77f89891a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3af22732-ff86-4ae2-813a-d2bcf0924471	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a01c237d-ae30-4326-9731-fde72505a4a6	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da22eb1-0965-4d4e-b15d-91db7193548e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	4	Unknown status	01/01/2010	https://clinicaltrials.gov/study/NCT00817466	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01834820	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	3	Recruiting	13/12/2018	https://clinicaltrials.gov/study/NCT03567473	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01873144	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT01016249	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiolitis	EPINEPHRINE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01276821	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute bronchiolitis	EPINEPHRINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01871857	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL CITRATE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03405090	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	chronic obstructive pulmonary disease	FENTANYL CITRATE	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03405090	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory system disease	FENTANYL CITRATE	targetBased	4	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05856136	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	respiratory system disease	FENTANYL CITRATE	targetBased	4	Recruiting	19/06/2023	https://clinicaltrials.gov/study/NCT05856136	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial lung disease	FENTANYL CITRATE	targetBased	3	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03018756	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial lung disease	FENTANYL CITRATE	targetBased	3	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03018756	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae35ec1f-526a-49bf-8262-c50e40190d1f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb952b7-8826-40a1-ac7b-38ec1bd9b94e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dc143e7-6bab-42c8-b3e9-9d604d202e73	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ffb3297-6d69-4475-9bb3-ccecf3ede614	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f090fb-c591-4d6a-98b7-925b0bb17c38	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254422f6-37e0-4dc1-ad3b-b2e20009a7b5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01836016	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e65e8c22-d9d9-4473-8240-cfd154b8e6c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01490125	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c2fe10-c61f-4cbe-bc45-7ab14baa691c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a90911e-adb5-4331-8d1a-f791fba549f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a56892b-7485-4570-9a1d-53ef23f07cbe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00400153	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	18/03/2011	https://clinicaltrials.gov/study/NCT01323621	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02103374	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcc9dbb-5758-4979-b84b-891f3d04f61e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69ffacaa-c7e5-4016-9e77-79f7d724baad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478683	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Recruiting	09/12/2020	https://clinicaltrials.gov/study/NCT04655170	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00669617	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acc9a53e-304d-44e4-b4ab-5303d1361118	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26138eb9-ff04-41cc-94c8-83edcba78b86	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bfd443-1d9d-4806-b044-6ff874b92b25	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Withdrawn	03/09/2021	https://clinicaltrials.gov/study/NCT04446637	0.7	GoF	protect	administrative decision
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c64255e-074c-41f8-a344-3686a0685020	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Terminated	01/10/2013	https://clinicaltrials.gov/study/NCT01969539	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e7c1e97-b8b2-44c0-aeac-18f9142a522b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	14/07/2016	https://clinicaltrials.gov/study/NCT02799784	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	15/10/2012	https://clinicaltrials.gov/study/NCT01706328	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	28/09/2017	https://clinicaltrials.gov/study/NCT03256695	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	23/07/2012	https://clinicaltrials.gov/study/NCT01691482	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478696	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab1cbed4-50c4-4769-9947-1927333f278c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3d2ab1e-8f91-4a4d-aa6b-5a57f59ad56b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e701d71-1dcb-4b84-bada-84e4f04f5e62	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9b20e4-82e6-4151-9c9d-39aaf2a767e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0d31515-28cf-4041-9007-a5a9b52dc78d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3544356-e36a-4ce6-8235-cb0531c658ad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=953ab65b-b157-41b3-8f90-98fa9d7f20c5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0ec9932-b2a3-4776-a7e8-2aeded019da4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	23/01/2015	https://clinicaltrials.gov/study/NCT02345161	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00665600	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=708615b8-79b1-4eaa-b765-abb01be3233a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=071e819b-43cd-48f7-b63e-c891936dcfc4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d215fe3-1cf6-4bb3-b005-75f1a9d62235	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ec64742-5802-49f0-bbbe-95580730c0a7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29f0d08e-14d7-4659-bc00-0d84ae69cb7f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23c05e9a-9df5-4978-8831-cf562aa4ba92	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	20/09/2017	https://clinicaltrials.gov/study/NCT03405090	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bcc115b-88da-4ff0-b4e1-ef10d5287e54	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	15/10/2014	https://clinicaltrials.gov/study/NCT02257385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d92c5d6b-ff10-4087-36a2-1cfc464cb967	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49edc01-1ea6-4f88-883a-bb4bc2bf4b3f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e439746-9808-4102-a92f-bf6c3f1e3513	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT02731846	0.7	GoF	protect	It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	29/06/2016	https://clinicaltrials.gov/study/NCT02729051	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133fb50a-68d3-4d1b-a47a-67d07cc48da5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Unknown status	20/06/2018	https://clinicaltrials.gov/study/NCT03745261	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=374cbcbb-a37c-4057-b9a9-f70b3fdb803c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5329614f-ae0b-4854-bb6f-ea0b7dae87c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b72742df-1a6b-4483-aff3-3e79db5e015d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f0d280b-747e-4232-9d4d-a5c964f0daad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01019694	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34b6ab14-9ed5-4651-9be6-84685e6aa919	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7c031a5-3bf8-4548-8fe7-0c308a45152a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01313494	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	02/12/2020	https://clinicaltrials.gov/study/NCT04606394	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1821db2-8a50-40e1-8448-4e59eafd2612	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00911651	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b2ff7e6-d9fb-47ed-85eb-859cb1bc8a79	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77f24a8c-0a9a-4708-a401-3f56b5d4f2c1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2b67032-2ad0-4db5-a8b5-f1d3943f65d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01253473	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Terminated	01/10/2000	https://clinicaltrials.gov/study/NCT02194205	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c53c391b-de2f-4df8-8c25-6764564580c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16efdd16-04db-4874-92de-d1de22aee074	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911f605d-5451-49e2-a484-00f619f2012b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=774b1ef9-015e-4e8e-9c52-d305de1ef85e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00462540	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22367ff1-5edf-429a-955a-728e42695f60	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53176c67-ebcd-4b07-a08a-f2df3c541af9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	29/03/2018	https://clinicaltrials.gov/study/NCT03474081	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8839cf1-ec1c-42e6-a4d3-b089e95337e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecc00500-58b8-491f-80df-dc6c89a08cae	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Unknown status	11/01/2019	https://clinicaltrials.gov/study/NCT03449056	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00359788	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	04/10/2006	https://clinicaltrials.gov/study/NCT00388882	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87b8cd3c-2849-4b50-b63e-9ea379165c07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad98bce-bb10-4a04-94e7-d6f55ae60cda	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atopic asthma	ALBUTEROL	targetBased	3	Completed	09/05/2018	https://clinicaltrials.gov/study/NCT03468790	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05f7916c-52f7-4a4f-a19b-f5e35f02fd0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574824f3-51cc-4b94-9c10-e3204d8b19f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bdda27b-e123-4f33-87e2-63f33b2b061e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d06309-0483-48c6-a9f2-b25dcc31db72	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938ab43d-bf4c-477f-b918-aabe738d562b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dee492-8bf9-4360-be9b-9d6ee1ecb256	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00354354	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT02177253	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	30/09/2014	https://clinicaltrials.gov/study/NCT02257372	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5daaf067-49a2-4067-afa4-39411c87524f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02182856	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c1f3881-2b68-4bdb-a12f-8134fe8ba961	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95d573-74b2-4b0e-9397-c2cdaf7f41e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9d01507-ae72-4322-93d5-5d857b1b2caa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb4f1002-9372-4fac-aea3-99142f93dd37	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f248b57a-2c06-4ed8-817e-e6ff42f5ce88	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f422539-5708-46fd-944d-c88a12fc5ec3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d6ba1a-1599-48a3-8dbd-a8b06af20fe1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afcf38bf-b183-4569-b43f-25deb97f6693	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a1cb095-c3c6-4629-9a88-aeae949541ef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74170607-50c0-4de5-847e-64da9b1d52db	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a801d6-9573-4997-9b4a-aec6db6459ed	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=285a656c-f77f-4e77-b0a8-a0e9c901803f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29d24a6d-f9c1-4300-97c7-fec26bdbc22b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=829f381a-7888-4579-a2c5-4359764813c3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f454947c-6055-474b-bf35-29a379e01aa3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58860ee1-5a9d-4422-b9bc-78e8b7958b53	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fe2669f-ca2a-fd31-e09c-fd2819a8308c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4	Completed	23/01/2015	https://clinicaltrials.gov/study/NCT02275052	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fbbb275-24a8-43c6-b341-baf90957cd69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute respiratory failure	ALBUTEROL	targetBased	4	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00600639	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC02	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=667ce3ec-5217-4b10-b712-f3e54fbbf087	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29d24a6d-f9c1-4300-97c7-fec26bdbc22b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a000abb9-92a1-4c84-8932-cd40c476dc00	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1700a5b8-4029-424a-bfed-15f6737dd210	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40f3cdbc-c9ee-4a3c-8061-a44b9a1d035c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ee98719-c248-4373-e053-2995a90ae626	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulmonary arterial hypertension	ALBUTEROL	targetBased	3	Withdrawn	01/07/2016	https://clinicaltrials.gov/study/NCT02782052	0.7	GoF	protect	Sponsor's decision
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=708615b8-79b1-4eaa-b765-abb01be3233a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Withdrawn	01/04/2022	https://clinicaltrials.gov/study/NCT05292976	0.7	GoF	protect	Business reasons
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c64255e-074c-41f8-a344-3686a0685020	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	15/05/2018	https://clinicaltrials.gov/study/NCT03816267	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00382889	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	15/10/2015	https://clinicaltrials.gov/study/NCT02528214	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9b20e4-82e6-4151-9c9d-39aaf2a767e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=829f381a-7888-4579-a2c5-4359764813c3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Withdrawn	07/03/2018	https://clinicaltrials.gov/study/NCT03363191	1	GoF	protect	The study was withdrawn due to an internal decision.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e701d71-1dcb-4b84-bada-84e4f04f5e62	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00528723	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7c031a5-3bf8-4548-8fe7-0c308a45152a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02126839	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00384189	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab1cbed4-50c4-4769-9947-1927333f278c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ec64742-5802-49f0-bbbe-95580730c0a7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22367ff1-5edf-429a-955a-728e42695f60	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	22/09/2018	https://clinicaltrials.gov/study/NCT03528577	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d06309-0483-48c6-a9f2-b25dcc31db72	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	13/02/2017	https://clinicaltrials.gov/study/NCT02969408	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5daaf067-49a2-4067-afa4-39411c87524f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3544356-e36a-4ce6-8235-cb0531c658ad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Not yet recruiting	11/12/2023	https://clinicaltrials.gov/study/NCT06154304	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01431950	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87b8cd3c-2849-4b50-b63e-9ea379165c07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	09/01/2012	https://clinicaltrials.gov/study/NCT01471340	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01907334	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01338311	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Terminated	01/09/1998	https://clinicaltrials.gov/study/NCT02235428	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00990847	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0ec9932-b2a3-4776-a7e8-2aeded019da4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01076322	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16efdd16-04db-4874-92de-d1de22aee074	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00588406	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4a92e7c-6d19-45e7-91f0-685f68383784	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	29/08/2018	https://clinicaltrials.gov/study/NCT03562195	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01698320	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00073827	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02031640	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b72742df-1a6b-4483-aff3-3e79db5e015d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00646009	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Withdrawn	01/09/1993	https://clinicaltrials.gov/study/NCT00000577	0.7	GoF	protect	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05f7916c-52f7-4a4f-a19b-f5e35f02fd0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	27/07/2020	https://clinicaltrials.gov/study/NCT04159519	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02584738	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6afb1ec5-6771-4ce7-accb-fdff05ebf3b9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	10/06/2006	https://clinicaltrials.gov/study/NCT00308685	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02141854	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c1f3881-2b68-4bdb-a12f-8134fe8ba961	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e65e8c22-d9d9-4473-8240-cfd154b8e6c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dc143e7-6bab-42c8-b3e9-9d604d202e73	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00487773	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29d24a6d-f9c1-4300-97c7-fec26bdbc22b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a90911e-adb5-4331-8d1a-f791fba549f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	13/10/2016	https://clinicaltrials.gov/study/NCT02924688	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecc00500-58b8-491f-80df-dc6c89a08cae	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00189436	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00830882	1	GoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02139644	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00900874	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acc9a53e-304d-44e4-b4ab-5303d1361118	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	11/05/2016	https://clinicaltrials.gov/study/NCT02741271	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=becf2107-bbc9-4b7b-87a5-3221ff6fc5cf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb4f1002-9372-4fac-aea3-99142f93dd37	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	13/12/2018	https://clinicaltrials.gov/study/NCT03769090	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a1cb095-c3c6-4629-9a88-aeae949541ef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Withdrawn	18/01/2019	https://clinicaltrials.gov/study/NCT03376932	0.7	GoF	protect	withdrawn due to internal reasons
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	17/05/2006	https://clinicaltrials.gov/study/NCT00363480	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	07/09/2015	https://clinicaltrials.gov/study/NCT02502734	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01424813	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05884970	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=071e819b-43cd-48f7-b63e-c891936dcfc4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29f0d08e-14d7-4659-bc00-0d84ae69cb7f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34b6ab14-9ed5-4651-9be6-84685e6aa919	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02040766	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f248b57a-2c06-4ed8-817e-e6ff42f5ce88	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254422f6-37e0-4dc1-ad3b-b2e20009a7b5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b2ff7e6-d9fb-47ed-85eb-859cb1bc8a79	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00646620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	31/01/2018	https://clinicaltrials.gov/study/NCT03380429	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e7c1e97-b8b2-44c0-aeac-18f9142a522b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=374cbcbb-a37c-4057-b9a9-f70b3fdb803c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d6ba1a-1599-48a3-8dbd-a8b06af20fe1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00685425	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f454947c-6055-474b-bf35-29a379e01aa3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae35ec1f-526a-49bf-8262-c50e40190d1f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bcc115b-88da-4ff0-b4e1-ef10d5287e54	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00124176	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	20/03/2019	https://clinicaltrials.gov/study/NCT03847896	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26138eb9-ff04-41cc-94c8-83edcba78b86	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00393367	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01747629	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00272753	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00064389	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133fb50a-68d3-4d1b-a47a-67d07cc48da5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d215fe3-1cf6-4bb3-b005-75f1a9d62235	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bfd443-1d9d-4806-b044-6ff874b92b25	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a801d6-9573-4997-9b4a-aec6db6459ed	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9d01507-ae72-4322-93d5-5d857b1b2caa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00073814	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1821db2-8a50-40e1-8448-4e59eafd2612	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Active, not recruiting	09/07/2021	https://clinicaltrials.gov/study/NCT04997304	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74170607-50c0-4de5-847e-64da9b1d52db	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00577655	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00252863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00667407	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fbbb275-24a8-43c6-b341-baf90957cd69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Recruiting	29/06/2021	https://clinicaltrials.gov/study/NCT04276233	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53176c67-ebcd-4b07-a08a-f2df3c541af9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5329614f-ae0b-4854-bb6f-ea0b7dae87c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad98bce-bb10-4a04-94e7-d6f55ae60cda	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634829	0.7	GoF	protect	IND voluntarily withdrawn, without prejudice
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95d573-74b2-4b0e-9397-c2cdaf7f41e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911f605d-5451-49e2-a484-00f619f2012b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dee492-8bf9-4360-be9b-9d6ee1ecb256	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8839cf1-ec1c-42e6-a4d3-b089e95337e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Terminated	01/10/2010	https://clinicaltrials.gov/study/NCT01218009	0.7	GoF	protect	Change to study required.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	26/12/2013	https://clinicaltrials.gov/study/NCT02040779	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d92c5d6b-ff10-4087-36a2-1cfc464cb967	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	22/06/2017	https://clinicaltrials.gov/study/NCT03184987	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	25/07/2007	https://clinicaltrials.gov/study/NCT00530062	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Terminated	01/09/2013	https://clinicaltrials.gov/study/NCT01951378	1	GoF	protect	No data are available for this study as the PI has left the institution.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00685126	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0d31515-28cf-4041-9007-a5a9b52dc78d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fe2669f-ca2a-fd31-e09c-fd2819a8308c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ffb3297-6d69-4475-9bb3-ccecf3ede614	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcc9dbb-5758-4979-b84b-891f3d04f61e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afcf38bf-b183-4569-b43f-25deb97f6693	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT01091337	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	04/11/2004	https://clinicaltrials.gov/study/NCT00315744	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Terminated	01/09/2007	https://clinicaltrials.gov/study/NCT00635505	0.7	GoF	protect	IND voluntarily withdrawn, without prejudice
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Unknown status	01/10/2006	https://clinicaltrials.gov/study/NCT00385359	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	30/09/2015	https://clinicaltrials.gov/study/NCT02513160	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb952b7-8826-40a1-ac7b-38ec1bd9b94e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49edc01-1ea6-4f88-883a-bb4bc2bf4b3f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02175771	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00861926	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23c05e9a-9df5-4978-8831-cf562aa4ba92	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02584257	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e439746-9808-4102-a92f-bf6c3f1e3513	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938ab43d-bf4c-477f-b918-aabe738d562b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT04750603	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00831376	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=953ab65b-b157-41b3-8f90-98fa9d7f20c5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT02182713	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/07/1993	https://clinicaltrials.gov/study/NCT00940927	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02654145	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	05/04/2017	https://clinicaltrials.gov/study/NCT03493503	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574824f3-51cc-4b94-9c10-e3204d8b19f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	16/02/2021	https://clinicaltrials.gov/study/NCT04677959	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205636s004lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2b67032-2ad0-4db5-a8b5-f1d3943f65d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58860ee1-5a9d-4422-b9bc-78e8b7958b53	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Recruiting	22/12/2023	https://clinicaltrials.gov/study/NCT06245551	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00144846	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	12/11/2012	https://clinicaltrials.gov/study/NCT01687296	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f0d280b-747e-4232-9d4d-a5c964f0daad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00497523	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00273962	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00634517	0.7	GoF	protect	IND voluntarily withdrawn, without prejudice
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f090fb-c591-4d6a-98b7-925b0bb17c38	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c53c391b-de2f-4df8-8c25-6764564580c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=285a656c-f77f-4e77-b0a8-a0e9c901803f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01096017	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=774b1ef9-015e-4e8e-9c52-d305de1ef85e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	14/11/2014	https://clinicaltrials.gov/study/NCT02233803	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69ffacaa-c7e5-4016-9e77-79f7d724baad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00394329	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f422539-5708-46fd-944d-c88a12fc5ec3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77f24a8c-0a9a-4708-a401-3f56b5d4f2c1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	09/10/2015	https://clinicaltrials.gov/study/NCT02483975	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	11/11/2021	https://clinicaltrials.gov/study/NCT05084222	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a56892b-7485-4570-9a1d-53ef23f07cbe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	3	Completed	27/04/2015	https://clinicaltrials.gov/study/NCT02414854	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Recruiting	20/02/2019	https://clinicaltrials.gov/study/NCT03822637	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3d2ab1e-8f91-4a4d-aa6b-5a57f59ad56b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bdda27b-e123-4f33-87e2-63f33b2b061e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c2fe10-c61f-4cbe-bc45-7ab14baa691c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL	targetBased	4	Completed	26/10/2020	https://clinicaltrials.gov/study/NCT03890666	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lung disease	ALBUTEROL	targetBased	3	Withdrawn	01/09/1993	https://clinicaltrials.gov/study/NCT00000577	0.7	GoF	protect	Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute bronchiolitis	ALBUTEROL	targetBased	4	Not yet recruiting	20/07/2020	https://clinicaltrials.gov/study/NCT03880903	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Status Asthmaticus	ALBUTEROL	targetBased	4	Completed	05/04/2017	https://clinicaltrials.gov/study/NCT03493503	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Status Asthmaticus	ALBUTEROL	targetBased	4	Terminated	10/09/2018	https://clinicaltrials.gov/study/NCT02966184	1	GoF	protect	Study Drug Backorder
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	CELIPROLOL	targetBased	4	Completed	07/06/2016	https://clinicaltrials.gov/study/NCT02380053	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	CARVEDILOL	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01656005	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		lung disease	KETAMINE	targetBased	3	Completed	01/09/2019	https://clinicaltrials.gov/study/NCT06185127	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Status Asthmaticus	KETAMINE	targetBased	3	Withdrawn	01/01/2020	https://clinicaltrials.gov/study/NCT03338205	0.7	LoF	protect	Unable to enroll patients
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pharyngitis	KETAMINE	targetBased	3	Completed	15/11/2018	https://clinicaltrials.gov/study/NCT03729973	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pharyngitis	KETAMINE	targetBased	3	Completed	19/08/2021	https://clinicaltrials.gov/study/NCT04955158	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		chronic obstructive pulmonary disease	KETAMINE	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT02962999	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		mucositis	KETAMINE	targetBased	3	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00474110	0.7	LoF	protect	Clinical practice had changed between time of initial protocol development and subject recruitment. We were not able to find eligible patients.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		acute respiratory failure	KETAMINE	targetBased	4	Recruiting	06/04/2022	https://clinicaltrials.gov/study/NCT05277896	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute respiratory distress syndrome	ESMOLOL	targetBased	3	Recruiting	20/02/2023	https://clinicaltrials.gov/study/NCT06013319	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ESMOLOL	targetBased	4	Not yet recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT05694585	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	METAPROTERENOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43ff5156-e08b-4dc4-93a6-8c727676daa1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	METAPROTERENOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf566e38-f6ff-4b86-9537-8684943b36eb	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Respiratory insufficiency	BUTORPHANOL	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05024799	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	BUTORPHANOL	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05024799	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	BUTORPHANOL	targetBased	4	Not yet recruiting	01/01/2022	https://clinicaltrials.gov/study/NCT05024799	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FENOTEROL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00274066	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FENOTEROL	targetBased	3	Terminated	01/04/2003	https://clinicaltrials.gov/study/NCT02176187	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FENOTEROL	targetBased	3	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02173782	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FENOTEROL	targetBased	3	Terminated	01/04/2003	https://clinicaltrials.gov/study/NCT02176200	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	FENOTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC04	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	FENOTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC04	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FENOTEROL	targetBased	3	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT02182505	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FENOTEROL	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT02182479	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FENOTEROL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01095016	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FENOTEROL	targetBased	3	Terminated	01/02/1990	https://clinicaltrials.gov/study/NCT02177370	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CALCITRIOL	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00712205	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	CLENBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC13	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	CLENBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC14	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB	targetBased	3	Completed	20/04/2011	https://clinicaltrials.gov/study/NCT01392469	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB	targetBased	3	Terminated	01/06/2011	https://clinicaltrials.gov/study/NCT01392495	0.7	LoF	protect	Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB	targetBased	3	Completed	22/01/2014	https://clinicaltrials.gov/study/NCT02042014	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00902174	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB	targetBased	3	Terminated	01/04/2010	https://clinicaltrials.gov/study/NCT01117987	0.7	LoF	protect	Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	non-allergic rhinitis	CAPSAICIN	targetBased	3	Recruiting	10/09/2019	https://clinicaltrials.gov/study/NCT05093478	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	non-allergic rhinitis	CAPSAICIN	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02288156	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rhinitis	CAPSAICIN	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01223820	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rhinitis	CAPSAICIN	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01862523	1		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	LEVOSALBUTAMOL	targetBased	3	Withdrawn	03/09/2021	https://clinicaltrials.gov/study/NCT04446637	0.7	GoF	protect	administrative decision
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	LEVOSALBUTAMOL	targetBased	3	Active, not recruiting	28/09/2023	https://clinicaltrials.gov/study/NCT06040424	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	LEVOSALBUTAMOL	targetBased	3	Recruiting	25/08/2023	https://clinicaltrials.gov/study/NCT05890638	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be7615b-70a5-4912-b4a5-09656cab2187	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	27/04/2015	https://clinicaltrials.gov/study/NCT02414854	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00073827	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c99a7f95-0092-48c1-9195-3431250633da	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00073814	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4cf6b3-36d4-4b41-84e9-682012d7e4e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1700a5b8-4029-424a-bfed-15f6737dd210	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b2b443-bdc7-4045-bb94-906199125f49	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4	Terminated	01/01/2009	https://clinicaltrials.gov/study/NCT00819637	1	GoF	protect	Unable to enroll r/t study design & staffing issues. The trial terminated.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00831376	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02150499	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT02170532	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6925ab5e-4f50-4d04-b55a-8a6f74474382	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35eb525b-72a5-4ef9-a36a-531e9e6b3560	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	15/10/2015	https://clinicaltrials.gov/study/NCT02528214	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00809757	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322c7883-f01b-4ce9-b667-4924717a4e6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91161c1-cae8-4d69-a37c-fb7b64b7736a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6be0f39e-eae0-4636-b1b3-1b31fe38301c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=206bbdec-04f0-40e3-a259-32fc6bce20d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00830882	1	GoF	protect	Lack of funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1e9d249-33d1-4b14-b92e-8f4dccded1da	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00585039	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00064389	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00073840	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b7537a3-409e-4d10-87db-302f05ce684e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24b4489f-9e6d-4895-bf8b-a6b31050b1b2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVOSALBUTAMOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c47c47d-45f7-4eb4-b1f8-7d6c633a1f69	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	REMIFENTANIL	targetBased	4	Unknown status	15/02/2019	https://clinicaltrials.gov/study/NCT03783676	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	REMIFENTANIL	targetBased	4	Unknown status	15/02/2019	https://clinicaltrials.gov/study/NCT03783676	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	REMIFENTANIL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00665119	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Respiratory insufficiency	REMIFENTANIL	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00665119	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	REMIFENTANIL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00391105	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	REMIFENTANIL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00391105	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CALCIFEDIOL	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02805907	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01248065	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CHOLECALCIFEROL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00504946	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CHOLECALCIFEROL	targetBased	4	Terminated	26/06/2015	https://clinicaltrials.gov/study/NCT02424552	1	GoF	protect	recruitment problems
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	CHOLECALCIFEROL	targetBased	3	Active, not recruiting	01/09/2009	https://clinicaltrials.gov/study/NCT00920621	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cystic fibrosis	CHOLECALCIFEROL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01880346	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cystic fibrosis	CHOLECALCIFEROL	targetBased	4	Completed	13/03/2020	https://clinicaltrials.gov/study/NCT04118010	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic obstructive pulmonary disease	CHOLECALCIFEROL	targetBased	4	Completed	18/02/2020	https://clinicaltrials.gov/study/NCT05431218	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic obstructive pulmonary disease	CHOLECALCIFEROL	targetBased	4	Withdrawn	01/09/2011	https://clinicaltrials.gov/study/NCT01416701	1	GoF	protect	It was not possible to enroll the planned amount of subjects. Many patients with chronic obstructive pulmonary disease already took large doses of vitamin D.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic obstructive pulmonary disease	CHOLECALCIFEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00914810	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	rhinitis	CHOLECALCIFEROL	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02272101	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Bronchiectasis	CHOLECALCIFEROL	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02507843	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	RIMITEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC05	1	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	respiratory failure	ISOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	respiratory failure	ISOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	SALMETEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	SALMETEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	SALMETEROL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01361984	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d9728e-6b5c-4aee-bfb0-745e542ed2e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Withdrawn	01/08/2011	https://clinicaltrials.gov/study/NCT01393145	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	13/06/2013	https://clinicaltrials.gov/study/NCT01879410	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709903	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00530842	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Unknown status	20/06/2018	https://clinicaltrials.gov/study/NCT03745261	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3beef422-8a07-4a45-9ba6-414511e4b7e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01536587	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/02/1999	https://clinicaltrials.gov/study/NCT02172287	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00144911	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	13/10/2015	https://clinicaltrials.gov/study/NCT02516592	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01762800	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Terminated	15/04/2008	https://clinicaltrials.gov/study/NCT00662740	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	30/04/2010	https://clinicaltrials.gov/study/NCT01110200	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02941679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	10/01/2017	https://clinicaltrials.gov/study/NCT02813200	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00527826	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02546349	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00864812	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e0bdea8-df9b-4873-b24b-919cebff5edd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	29/10/2009	https://clinicaltrials.gov/study/NCT00984659	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01245569	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00379028	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01908140	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	18/03/2011	https://clinicaltrials.gov/study/NCT01323621	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de811b6d-ca0e-4921-a127-b10101ee0035	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00821093	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01089127	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00269126	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT02136875	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00268177	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00361959	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/02/1999	https://clinicaltrials.gov/study/NCT02173691	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT01853787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	14/08/2017	https://clinicaltrials.gov/study/NCT03240575	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Withdrawn	01/12/2013	https://clinicaltrials.gov/study/NCT01860066	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00274560	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	29/03/2017	https://clinicaltrials.gov/study/NCT03055988	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00542880	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00685841	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Terminated	01/12/2006	https://clinicaltrials.gov/study/NCT00346749	1	GoF	protect	The study was terminated due to difficulties with finding sites and subjects willing to participate.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01342913	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20c1d84-5c49-47de-bd2e-f987ff67faef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00115492	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	28/04/2004	https://clinicaltrials.gov/study/NCT00355342	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	20/11/2015	https://clinicaltrials.gov/study/NCT02603393	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	15/10/2012	https://clinicaltrials.gov/study/NCT01706328	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT01243788	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00549146	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01186653	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00975195	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01969721	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00567996	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00669617	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	15/04/2008	https://clinicaltrials.gov/study/NCT00662792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	22/03/2018	https://clinicaltrials.gov/study/NCT03395002	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Withdrawn	01/12/2013	https://clinicaltrials.gov/study/NCT01834885	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eeb5f6a-593f-4a9e-9692-adefa2caf8fc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00673478	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00239499	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00274534	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01555138	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02972476	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	14/11/2013	https://clinicaltrials.gov/study/NCT01978145	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02477397	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00411372	0.7	GoF	protect	No subjects enrolled. Study was canceled before active
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01817764	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atopic asthma	SALMETEROL	targetBased	3	Completed	09/05/2018	https://clinicaltrials.gov/study/NCT03468790	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f7253f0-fbea-434f-b28f-e78f201b032c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	16/06/2017	https://clinicaltrials.gov/study/NCT03034915	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01772134	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Terminated	13/04/2018	https://clinicaltrials.gov/study/NCT03363503	1	GoF	protect	Adequate number of patients could not be reached in the relevant centers.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f53cb2d5-3267-401e-9393-dff8357830dd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01836016	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Terminated	01/04/2000	https://clinicaltrials.gov/study/NCT00158847	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00563381	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00268216	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	28/01/2005	https://clinicaltrials.gov/study/NCT00269087	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	30/05/2014	https://clinicaltrials.gov/study/NCT02055352	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02270424	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4925b2c-bde1-45fd-8109-dc75bee3b7a3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00615030	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01751113	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00239421	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00784550	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01772147	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Unknown status	01/12/2009	https://clinicaltrials.gov/study/NCT01131806	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	18/03/2011	https://clinicaltrials.gov/study/NCT01323634	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT02172794	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00358358	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe9d76-1b0e-47a4-831d-097168d66577	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	19/07/2010	https://clinicaltrials.gov/study/NCT01124422	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00525564	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00633217	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00876694	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01344655	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00622635	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Completed	04/04/2013	https://clinicaltrials.gov/study/NCT01822899	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL	targetBased	3	Terminated	15/04/2008	https://clinicaltrials.gov/study/NCT00668772	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	SALMETEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC12	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00156819	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00327353	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Recruiting	30/01/2023	https://clinicaltrials.gov/study/NCT05664061	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01696214	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00370591	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00291382	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfaca6f9-3277-47b2-319d-1377917cb54c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00395304	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00901368	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Terminated	08/11/2004	https://clinicaltrials.gov/study/NCT00273026	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262587	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20c1d84-5c49-47de-bd2e-f987ff67faef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00200967	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01437995	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00480649	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00920543	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01194700	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00452699	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00950794	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00914901	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00169546	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00404261	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3beef422-8a07-4a45-9ba6-414511e4b7e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00127166	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02388373	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01647646	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f53cb2d5-3267-401e-9393-dff8357830dd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00197106	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01202097	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Terminated	01/03/2006	https://clinicaltrials.gov/study/NCT00471809	0.5	GoF	protect	The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a futility analysis with 55 randomized children.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01181895	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00829257	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	04/11/2004	https://clinicaltrials.gov/study/NCT00315744	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00646620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00449046	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00517634	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00296491	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01892787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00441441	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00102765	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01172821	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00245570	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00452348	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	03/12/2018	https://clinicaltrials.gov/study/NCT03756883	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00529529	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02245672	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Withdrawn	01/09/2015	https://clinicaltrials.gov/study/NCT02496715	0.7	GoF	protect	Development terminated.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT01324362	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe9d76-1b0e-47a4-831d-097168d66577	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Terminated	01/07/2017	https://clinicaltrials.gov/study/NCT03269318	1	GoF	protect	Change to Primary Endpoint resulted in development of new protocol
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00646009	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00479739	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00328718	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00252863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e0bdea8-df9b-4873-b24b-919cebff5edd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02554786	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Recruiting	01/10/2007	https://clinicaltrials.gov/study/NCT01225913	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Recruiting	23/07/2021	https://clinicaltrials.gov/study/NCT04503460	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00461500	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT01255579	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	18/11/2005	https://clinicaltrials.gov/study/NCT00353873	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00296530	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01274325	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	09/07/2015	https://clinicaltrials.gov/study/NCT02446418	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02141854	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00242775	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f7253f0-fbea-434f-b28f-e78f201b032c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00646594	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	30/03/2011	https://clinicaltrials.gov/study/NCT01290874	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00448435	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01172808	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac79cc13-4241-427c-a69b-6b00dafcef00	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Terminated	31/08/2015	https://clinicaltrials.gov/study/NCT02491970	1	GoF	protect	Difficulty of patients enrollments
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	17/10/2018	https://clinicaltrials.gov/study/NCT03394989	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eeb5f6a-593f-4a9e-9692-adefa2caf8fc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	13/10/2016	https://clinicaltrials.gov/study/NCT02924688	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01795664	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02301975	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a27267-2f2b-410d-9c30-9cb95f35d9a1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	26/07/2005	https://clinicaltrials.gov/study/NCT00351143	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01147848	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01526161	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4925b2c-bde1-45fd-8109-dc75bee3b7a3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00920959	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00565266	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01511367	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	16/02/2021	https://clinicaltrials.gov/study/NCT04677959	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00497237	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00708227	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00379288	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00830505	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	03/05/2005	https://clinicaltrials.gov/study/NCT00455923	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03461627	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00394368	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	17/05/2006	https://clinicaltrials.gov/study/NCT00363480	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Terminated	01/10/2007	https://clinicaltrials.gov/study/NCT00503009	1	GoF	protect	lack of data
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d9728e-6b5c-4aee-bfb0-745e542ed2e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	06/11/2013	https://clinicaltrials.gov/study/NCT01978119	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Recruiting	02/06/2017	https://clinicaltrials.gov/study/NCT03387241	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/11/1999	https://clinicaltrials.gov/study/NCT00158834	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de811b6d-ca0e-4921-a127-b10101ee0035	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02113436	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	28/12/2016	https://clinicaltrials.gov/study/NCT02980133	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00424008	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01079130	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01570478	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	08/12/2015	https://clinicaltrials.gov/study/NCT02571777	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00102882	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01484210	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02061280	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL	targetBased	3	Withdrawn	18/01/2019	https://clinicaltrials.gov/study/NCT03376932	0.7	GoF	protect	withdrawn due to internal reasons
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	SALMETEROL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01361984	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	SALMETEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	SALMETEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	SALMETEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	PROCATEROL	targetBased	4	Not yet recruiting	16/04/2024	https://clinicaltrials.gov/study/NCT06346691	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	PROCATEROL	targetBased	4	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00394485	1	GoF	protect	Difficulty in recruting patients
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	PROCATEROL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=R03AC16	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	PROCATEROL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=R03CC08	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROCATEROL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT01091337	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROCATEROL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01095016	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROCATEROL	targetBased	4	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01170429	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROCATEROL	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00990847	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PROCATEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01076322	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01361984	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00754546	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00931385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773786	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Terminated	01/11/2014	https://clinicaltrials.gov/study/NCT02275481	1	GoF	protect	lack of enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00909779	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00571428	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00932646	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00685841	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL	targetBased	4	Terminated	03/10/2017	https://clinicaltrials.gov/study/NCT03219866	1	GoF	protect	Lower enrollment than Sponsor expected - Sponsor stopped study
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ARFORMOTEROL	targetBased	4	Terminated	01/01/2009	https://clinicaltrials.gov/study/NCT00819637	1	GoF	protect	Unable to enroll r/t study design & staffing issues. The trial terminated.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ARFORMOTEROL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00734318	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ARFORMOTEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00563056	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL	targetBased	4	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT01361984	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00064415	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	ARFORMOTEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal congestion	EPHEDRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R01AB05	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal congestion	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal congestion	EPHEDRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R01AA03	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4a4021c-c092-41bf-91ed-ef483fd52732	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73b55902-273a-4734-8deb-af6eb68b5523	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=750f9a39-acdc-4abc-800e-467884a4dcea	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46633af4-98c1-471f-9232-d719c6d8e445	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=172e970d-6773-4796-a280-3370e2f46c69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2170f081-c03f-47e8-bc63-4052c5e653fa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	common cold	EPHEDRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	pulmonary arterial hypertension	VASOPRESSIN	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT05439460	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30d4c387-b99c-49f8-a8bd-de23fdafb739	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ca799f1-7029-4527-9ab4-7512504bb8e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	acute respiratory distress syndrome	NOREPINEPHRINE	targetBased	4	Recruiting	01/10/2022	https://clinicaltrials.gov/study/NCT05658692	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	HYDROCODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Cough	HYDROCODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA03	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Cough	HYDROCODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R05DA03	1	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	TRHR	Thyrotropin-releasing hormone receptor	acute respiratory distress syndrome	PROTIRELIN	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00004778	0.7	GoF	protect
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	TRHR	Thyrotropin-releasing hormone receptor	acute respiratory distress syndrome	PROTIRELIN	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00004778	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	mucositis	HYDROMORPHONE	targetBased	3	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00474110	0.7	GoF	protect	Clinical practice had changed between time of initial protocol development and subject recruitment. We were not able to find eligible patients.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	mucositis	HYDROMORPHONE	targetBased	3	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00474110	0.7	GoF	protect	Clinical practice had changed between time of initial protocol development and subject recruitment. We were not able to find eligible patients.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	altitude sickness	NIFEDIPINE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02463357	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	lung disease	HYDROXYCHLOROQUINE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	acute respiratory distress syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	17/03/2020	https://clinicaltrials.gov/study/NCT04308668	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	acute respiratory distress syndrome	HYDROXYCHLOROQUINE	targetBased	3	Completed	06/04/2020	https://clinicaltrials.gov/study/NCT04328467	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	adult acute respiratory distress syndrome	HYDROXYCHLOROQUINE	targetBased	3	Terminated	17/04/2020	https://clinicaltrials.gov/study/NCT04347980	0.35	LoF	protect	ANSM RECOMMANDATION
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	respiratory failure	HYDROXYCHLOROQUINE	targetBased	3	Terminated	13/05/2020	https://clinicaltrials.gov/study/NCT04339816	0.35	LoF	protect	Steering Committee decision in accordance with stopping rule 1: Emergence of new data
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	ERGOCALCIFEROL	targetBased	4	Unknown status	01/03/2014	https://clinicaltrials.gov/study/NCT02053402	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	ERGOCALCIFEROL	targetBased	3	Active, not recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03365687	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	ERGOCALCIFEROL	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01447173	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	ERGOCALCIFEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01730976	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	BAMBUTEROL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01796730	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	BAMBUTEROL	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=R03CC12	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	BAMBUTEROL	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT02002754	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	BAMBUTEROL	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT02002754	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB MESYLATE	targetBased	3	Completed	22/01/2014	https://clinicaltrials.gov/study/NCT02042014	0.7	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	pulmonary arterial hypertension	IMATINIB MESYLATE	targetBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00902174	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	lung disease	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Withdrawn	30/04/2020	https://clinicaltrials.gov/study/NCT04361461	0.7	LoF	protect	This study was canceled before enrollment due to a decision by the Sponsor
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	respiratory system disease	DOXAPRAM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R07AB01	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	lung disease	DOXAPRAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Apnea	DOXAPRAM	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	lung disease	DOXAPRAM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypoxia	DOXAPRAM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02171910	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Apnea	DOXAPRAM	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	respiratory system disease	DOXAPRAM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R07AB01	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypoxia	DOXAPRAM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02171910	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	TERBUTALINE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02103374	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	TERBUTALINE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01944033	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	TERBUTALINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00421122	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	TERBUTALINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC03	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	TERBUTALINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC03	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	TERBUTALINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC53	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbf54709-5857-4dbc-9233-ebd7abff88c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94742710-e87e-4e1c-85ee-0a2e7a77f0de	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00849095	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7474ef3d-036f-47dd-aea7-be6d1086c0e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=382dcebb-6e41-4335-818d-b5822e3fb884	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00839800	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00244608	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	07/07/2014	https://clinicaltrials.gov/study/NCT02149199	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00914797	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00252863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00259766	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	28/11/2014	https://clinicaltrials.gov/study/NCT02224157	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00837967	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613df3cb-4d55-4d12-ab08-a932481aaa0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4be57a-a3df-4aa5-be52-845b75e78b3b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02322788	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Terminated	23/08/2021	https://clinicaltrials.gov/study/NCT04705727	0.7	GoF	protect	Not enough recruitment in th trial
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=879be756-991a-42c5-a381-9c8c2ad1fbdb	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8265c67f-55bc-40f0-9ede-3e4b4bb178f4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=352e3476-2bc4-4995-9fd9-4a8864417f1a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2af9a9-8bc4-4c6a-b8df-e8fc88c93d6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01096017	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	TERBUTALINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Status Asthmaticus	TERBUTALINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00124995	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	OLODATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01696058	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00932646	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00931385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01533922	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01040689	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT02853123	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02006732	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e15aee-40e0-23f3-537f-c96dd63e2cb1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03152149	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01040728	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	12/02/2016	https://clinicaltrials.gov/study/NCT02629965	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	13/01/2015	https://clinicaltrials.gov/study/NCT02296138	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02085161	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00796653	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00793624	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01040793	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	29/03/2017	https://clinicaltrials.gov/study/NCT03055988	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT02683109	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01040130	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00782210	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01536262	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	08/01/2020	https://clinicaltrials.gov/study/NCT04223843	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01431287	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00782509	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Withdrawn	01/08/2016	https://clinicaltrials.gov/study/NCT02812862	1	GoF	protect	Rationale obsolete
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	14/08/2017	https://clinicaltrials.gov/study/NCT03240575	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01559116	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01525615	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	28/01/2020	https://clinicaltrials.gov/study/NCT04231214	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	4	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03425617	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01964352	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01694771	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01533935	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01969721	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01431274	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	OLODATEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC19	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	OLODATEROL	targetBased	4	Completed	11/07/2016	https://clinicaltrials.gov/study/NCT02682862	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	OLODATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	PIRBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	PIRBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC08	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PIRBUTEROL	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/19009s6lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	REPROTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC14	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	REPROTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC15	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	INDACATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00821093	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01727024	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	05/02/2013	https://clinicaltrials.gov/study/NCT01794780	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00876694	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00624286	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01089127	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00393458	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00846586	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Withdrawn	01/11/2012	https://clinicaltrials.gov/study/NCT01715311	1	GoF	protect	withdrawn prior to patient recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01294787	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02665130	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02547558	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00792805	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00622635	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT05506865	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01072448	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00900731	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	30/05/2014	https://clinicaltrials.gov/study/NCT02055352	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	23/03/2013	https://clinicaltrials.gov/study/NCT02566031	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00877383	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01555138	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01693003	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01068600	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	28/04/2015	https://clinicaltrials.gov/study/NCT02418468	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00677807	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01012765	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Withdrawn	01/09/2011	https://clinicaltrials.gov/study/NCT01377428	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01232894	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT02473237	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00794157	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01543828	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01272362	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01437748	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00845728	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00999908	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01682863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00615459	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00620022	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00615030	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00567996	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00669617	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	15/10/2014	https://clinicaltrials.gov/study/NCT02257385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	INDACATEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC18	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiectasis	INDACATEROL	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	25/04/2017	https://clinicaltrials.gov/study/NCT03100500	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01079130	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02039011	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02554786	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00529529	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	INDACATEROL	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	GoF	protect	issues related to Covid-19 restrictions/shutdowns
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	INDACATEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4	Completed	10/01/2017	https://clinicaltrials.gov/study/NCT02813200	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe9d76-1b0e-47a4-831d-097168d66577	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01344655	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f7253f0-fbea-434f-b28f-e78f201b032c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00975195	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20c1d84-5c49-47de-bd2e-f987ff67faef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de811b6d-ca0e-4921-a127-b10101ee0035	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d9728e-6b5c-4aee-bfb0-745e542ed2e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4	Completed	30/04/2010	https://clinicaltrials.gov/study/NCT01110200	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01245569	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e0bdea8-df9b-4873-b24b-919cebff5edd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3beef422-8a07-4a45-9ba6-414511e4b7e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atopic asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	09/05/2018	https://clinicaltrials.gov/study/NCT03468790	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	3	Withdrawn	01/08/2011	https://clinicaltrials.gov/study/NCT01393145	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4925b2c-bde1-45fd-8109-dc75bee3b7a3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f53cb2d5-3267-401e-9393-dff8357830dd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00269126	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eeb5f6a-593f-4a9e-9692-adefa2caf8fc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4eeb5f6a-593f-4a9e-9692-adefa2caf8fc	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02113436	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00901368	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Terminated	08/11/2004	https://clinicaltrials.gov/study/NCT00273026	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01647646	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01484210	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b20c1d84-5c49-47de-bd2e-f987ff67faef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00452348	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d9728e-6b5c-4aee-bfb0-745e542ed2e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00394368	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4925b2c-bde1-45fd-8109-dc75bee3b7a3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00461500	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	03/05/2005	https://clinicaltrials.gov/study/NCT00455923	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01202097	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01795664	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	29/12/2015	https://clinicaltrials.gov/study/NCT02554786	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00127166	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de811b6d-ca0e-4921-a127-b10101ee0035	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac79cc13-4241-427c-a69b-6b00dafcef00	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00262587	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e0bdea8-df9b-4873-b24b-919cebff5edd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00565266	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03461627	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3beef422-8a07-4a45-9ba6-414511e4b7e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02245672	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f7253f0-fbea-434f-b28f-e78f201b032c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01511367	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bfe9d76-1b0e-47a4-831d-097168d66577	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00452699	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00829257	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfaca6f9-3277-47b2-319d-1377917cb54c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01274325	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f53cb2d5-3267-401e-9393-dff8357830dd	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Recruiting	23/07/2021	https://clinicaltrials.gov/study/NCT04503460	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a27267-2f2b-410d-9c30-9cb95f35d9a1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	SALMETEROL XINAFOATE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00102882	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	SALMETEROL XINAFOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58ed5fef-3da7-41d2-850d-55f72efcdb78	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	VILANTEROL TRIFENATATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL TRIFENATATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL TRIFENATATE	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	GoF	protect	Continuing delays due to COVID-19 pandemic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL TRIFENATATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL TRIFENATATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL TRIFENATATE	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01498679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	VILANTEROL TRIFENATATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	TULOBUTEROL	targetBased	4	Unknown status	01/11/2010	https://clinicaltrials.gov/study/NCT01465906	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	TULOBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC11	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	TULOBUTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC11	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TULOBUTEROL	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00950794	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	VILANTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316900	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01716520	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478696	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	04/03/2011	https://clinicaltrials.gov/study/NCT01336608	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	25/09/2009	https://clinicaltrials.gov/study/NCT01009463	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	13/03/2012	https://clinicaltrials.gov/study/NCT01551758	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01313637	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03152149	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	28/01/2014	https://clinicaltrials.gov/study/NCT01957150	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	05/10/2009	https://clinicaltrials.gov/study/NCT01053988	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	25/01/2011	https://clinicaltrials.gov/study/NCT01313676	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	06/06/2023	https://clinicaltrials.gov/study/NCT04923347	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	30/06/2011	https://clinicaltrials.gov/study/NCT01395888	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01691885	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	29/06/2016	https://clinicaltrials.gov/study/NCT02729051	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	07/04/2014	https://clinicaltrials.gov/study/NCT02105974	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	15/10/2012	https://clinicaltrials.gov/study/NCT01706328	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	11/04/2018	https://clinicaltrials.gov/study/NCT03467425	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	14/10/2022	https://clinicaltrials.gov/study/NCT05535972	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01627327	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	16/03/2011	https://clinicaltrials.gov/study/NCT01323660	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	18/03/2011	https://clinicaltrials.gov/study/NCT01323621	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	23/01/2015	https://clinicaltrials.gov/study/NCT02345161	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01817764	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01328444	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01342913	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	28/07/2015	https://clinicaltrials.gov/study/NCT02487446	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01376245	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478683	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	18/03/2011	https://clinicaltrials.gov/study/NCT01323634	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	25/09/2009	https://clinicaltrials.gov/study/NCT01017952	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	23/01/2013	https://clinicaltrials.gov/study/NCT01777334	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	19/10/2009	https://clinicaltrials.gov/study/NCT01054885	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02014480	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT05342558	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	04/04/2013	https://clinicaltrials.gov/study/NCT01822899	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	GoF	protect	Continuing delays due to COVID-19 pandemic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	27/07/2015	https://clinicaltrials.gov/study/NCT02487498	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	15/09/2014	https://clinicaltrials.gov/study/NCT01899742	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	4	Completed	29/03/2018	https://clinicaltrials.gov/study/NCT03474081	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT02731846	0.7	GoF	protect	It has been determined on June 10th that the 205165 study will not progress. This decision has been made prior to study start, no patients were screened.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	VILANTEROL	targetBased	3	Completed	30/06/2014	https://clinicaltrials.gov/study/NCT02164513	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01147848	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01181895	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02094937	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Active, not recruiting	08/08/2022	https://clinicaltrials.gov/study/NCT04651777	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	20/10/2017	https://clinicaltrials.gov/study/NCT03248128	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Recruiting	29/07/2021	https://clinicaltrials.gov/study/NCT04937387	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01498679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Withdrawn	18/01/2019	https://clinicaltrials.gov/study/NCT03376932	0.7	GoF	protect	withdrawn due to internal reasons
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	4	Completed	25/05/2016	https://clinicaltrials.gov/study/NCT02730351	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02301975	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	20/09/2012	https://clinicaltrials.gov/study/NCT01686633	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01435902	0.7	GoF	protect	Study was cancelled prior to enrolling any subjects
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01134042	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	20/08/2010	https://clinicaltrials.gov/study/NCT01165138	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	4	Withdrawn	07/03/2018	https://clinicaltrials.gov/study/NCT03363191	1	GoF	protect	The study was withdrawn due to an internal decision.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	13/10/2016	https://clinicaltrials.gov/study/NCT02924688	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	15/06/2016	https://clinicaltrials.gov/study/NCT02753712	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	4	Completed	13/10/2017	https://clinicaltrials.gov/study/NCT03315000	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	22/06/2017	https://clinicaltrials.gov/study/NCT03184987	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	09/07/2015	https://clinicaltrials.gov/study/NCT02446418	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01498653	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT04750603	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96428df1-ea05-431a-98d3-1ec2c4b63878	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	VILANTEROL	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01706198	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	VILANTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	PIRBUTEROL ACETATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/19009s6lbl.pdf	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ca799f1-7029-4527-9ab4-7512504bb8e2	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30d4c387-b99c-49f8-a8bd-de23fdafb739	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	Nasal congestion	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b	1	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Cough	SEVOFLURANE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01792063	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Laryngospasm	SEVOFLURANE	targetBased	4	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00665418	1		protect	Recruitment finished earlier, because all 40 patients enrolled
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Laryngospasm	SEVOFLURANE	targetBased	4	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00665418	1		protect	Recruitment finished earlier, because all 40 patients enrolled
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	respiratory failure	SEVOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Cough	SEVOFLURANE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01792063	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Active, not recruiting	03/05/2020	https://clinicaltrials.gov/study/NCT04235608	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	acute respiratory distress syndrome	SEVOFLURANE	targetBased	4	Terminated	16/04/2020	https://clinicaltrials.gov/study/NCT04359862	1		protect	Low recruitment ratio
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Suspended	14/03/2022	https://clinicaltrials.gov/study/NCT05259631	0.7		protect	Financial problems
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	acute respiratory distress syndrome	SEVOFLURANE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02166853	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Recruiting	24/07/2023	https://clinicaltrials.gov/study/NCT05849779	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	respiratory failure	SEVOFLURANE	targetBased	3	Recruiting	15/06/2020	https://clinicaltrials.gov/study/NCT04415060	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Suspended	14/03/2022	https://clinicaltrials.gov/study/NCT05259631	0.7		protect	Financial problems
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Active, not recruiting	03/05/2020	https://clinicaltrials.gov/study/NCT04235608	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	acute respiratory distress syndrome	SEVOFLURANE	targetBased	4	Terminated	16/04/2020	https://clinicaltrials.gov/study/NCT04359862	1		protect	Low recruitment ratio
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	acute respiratory distress syndrome	SEVOFLURANE	targetBased	3	Recruiting	24/07/2023	https://clinicaltrials.gov/study/NCT05849779	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	acute respiratory distress syndrome	SEVOFLURANE	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02166853	1		protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRROLATE	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRROLATE	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00585039	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c99a7f95-0092-48c1-9195-3431250633da	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6be0f39e-eae0-4636-b1b3-1b31fe38301c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=206bbdec-04f0-40e3-a259-32fc6bce20d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6925ab5e-4f50-4d04-b55a-8a6f74474382	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b7537a3-409e-4d10-87db-302f05ce684e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35eb525b-72a5-4ef9-a36a-531e9e6b3560	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3ce78d9-e923-400e-b3cd-3e6124ac7f6d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322c7883-f01b-4ce9-b667-4924717a4e6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24b4489f-9e6d-4895-bf8b-a6b31050b1b2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c47c47d-45f7-4eb4-b1f8-7d6c633a1f69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be7615b-70a5-4912-b4a5-09656cab2187	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d91161c1-cae8-4d69-a37c-fb7b64b7736a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b2b443-bdc7-4045-bb94-906199125f49	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c4cf6b3-36d4-4b41-84e9-682012d7e4e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1e9d249-33d1-4b14-b92e-8f4dccded1da	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1700a5b8-4029-424a-bfed-15f6737dd210	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	acute respiratory distress syndrome	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06037330	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ISOETHARINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC06	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	ISOETHARINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	BITOLTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC17	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Airway obstruction	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03BB06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic bronchitis	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	Bronchiectasis	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	01/09/2020	https://clinicaltrials.gov/study/NCT04509661	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01154127	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=260e843d-a627-4cb1-8cab-4f0537d1ca5e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02872090	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566604	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02181023	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01715298	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01709864	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01697696	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01922271	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01604278	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01119937	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2013	https://clinicaltrials.gov/study/NCT01757015	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01120691	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02576626	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	08/04/2021	https://clinicaltrials.gov/study/NCT04606901	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/08/2017	https://clinicaltrials.gov/study/NCT02867761	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01005901	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT01837927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	24/06/2015	https://clinicaltrials.gov/study/NCT02371629	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	26/09/2014	https://clinicaltrials.gov/study/NCT02236611	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01959516	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78166def-5e2f-42a6-a1f1-0253e5765632	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01712516	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	LoF	protect	Recruitment challenges
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01513460	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01202188	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01315249	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01613326	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01529632	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	LoF	protect	Continuing delays due to COVID-19 pandemic
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01699685	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00929110	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03364829	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727141	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7579de3d-caad-4697-b429-760db3e68a23	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04206761	0.7	LoF	protect	issues related to Covid-19 restrictions/shutdowns
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02953041	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Not yet recruiting	23/12/2024	https://clinicaltrials.gov/study/NCT05776927	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	05/02/2018	https://clinicaltrials.gov/study/NCT03158311	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Completed	28/04/2017	https://clinicaltrials.gov/study/NCT03100825	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02622243	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	asthma	GLYCOPYRRONIUM	targetBased	3	Withdrawn	01/03/2015	https://clinicaltrials.gov/study/NCT02127697	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	cystic fibrosis	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	02/05/2023	https://clinicaltrials.gov/study/NCT05704036	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	cystic fibrosis	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	02/05/2023	https://clinicaltrials.gov/study/NCT05704036	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	cystic fibrosis	ESTROGENS, CONJUGATED	targetBased	4	Recruiting	02/05/2023	https://clinicaltrials.gov/study/NCT05704036	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pharyngitis	TRAMADOL	targetBased	4	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT04991493	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pharyngitis	TRAMADOL	targetBased	4	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT04991493	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pharyngitis	TRAMADOL HYDROCHLORIDE	targetBased	4	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT04991493	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pharyngitis	TRAMADOL HYDROCHLORIDE	targetBased	4	Recruiting	10/09/2021	https://clinicaltrials.gov/study/NCT04991493	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL	targetBased	4	Withdrawn	01/03/2008	https://clinicaltrials.gov/study/NCT00633776	1	GoF	protect	Sponsor withdrew funding prior to study initiation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00680056	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	23/01/2015	https://clinicaltrials.gov/study/NCT02345161	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Unknown status	13/06/2018	https://clinicaltrials.gov/study/NCT03551197	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	27/03/2017	https://clinicaltrials.gov/study/NCT03081156	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01204034	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Withdrawn	04/12/2017	https://clinicaltrials.gov/study/NCT03181880	1	GoF	protect	Study stopped early as AZ have re-prioritised to focus on research to help bring existing and innovative medicines to more patients with asthma and COPD.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	05/02/2013	https://clinicaltrials.gov/study/NCT01794780	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	31/05/2018	https://clinicaltrials.gov/study/NCT03573817	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01415518	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02796677	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00561886	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02972476	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00383435	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00680056	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01186653	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00215436	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01656005	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT01836016	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01946620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	14/12/2016	https://clinicaltrials.gov/study/NCT03197818	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00476099	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00206154	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00462540	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01253473	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00996697	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00308191	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Not yet recruiting	28/02/2026	https://clinicaltrials.gov/study/NCT06234345	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02268396	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	25/08/2015	https://clinicaltrials.gov/study/NCT02533505	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01574651	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT01917331	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00972140	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02477397	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01908140	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Recruiting	09/12/2020	https://clinicaltrials.gov/study/NCT04655170	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01787097	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00379028	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01462942	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00239421	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00259779	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01760304	1	GoF	protect	Sponsor decided to stop the study due to expiration of blinded placebo .
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00932646	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01572792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT03028701	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00496470	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	24/01/2017	https://clinicaltrials.gov/study/NCT03022097	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	GoF	protect	Continuing delays due to COVID-19 pandemic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00393458	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00929851	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01488019	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01351792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT01853787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00215449	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	31/10/2014	https://clinicaltrials.gov/study/NCT04520230	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00280371	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Recruiting	21/02/2024	https://clinicaltrials.gov/study/NCT06283966	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00542880	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01854645	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478696	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Withdrawn	01/09/2011	https://clinicaltrials.gov/study/NCT01377428	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/08/2016	https://clinicaltrials.gov/study/NCT02988869	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00796653	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	19/09/2011	https://clinicaltrials.gov/study/NCT01437540	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01397890	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00628862	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01047553	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00793624	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00489853	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01245569	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Recruiting	07/07/2017	https://clinicaltrials.gov/study/NCT03275116	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02497001	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00139932	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	25/06/2018	https://clinicaltrials.gov/study/NCT03478683	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01437397	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00421122	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00507234	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00383721	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00419744	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01070784	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00134979	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	GoF	protect	Recruitment challenges
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	27/04/2015	https://clinicaltrials.gov/study/NCT02424344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb24d6b0-0d69-4a3c-a7f4-a35ca4804657	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Withdrawn	01/08/2011	https://clinicaltrials.gov/study/NCT01393145	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02526758	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00206167	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01069289	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01748279	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00931385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	3	Completed	27/06/2014	https://clinicaltrials.gov/study/NCT02157935	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	FORMOTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03AC13	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Airway obstruction	FORMOTEROL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R03CC15	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiectasis	FORMOTEROL	targetBased	3	Terminated	29/01/2019	https://clinicaltrials.gov/study/NCT03846570	0.7	GoF	protect	Insufficient inclusion rate (due to COVID-19 pandemic)
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Bronchiectasis	FORMOTEROL	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01769898	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00479739	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00747318	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00413387	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00326053	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00490243	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00383552	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00563056	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Recruiting	01/10/2007	https://clinicaltrials.gov/study/NCT01225913	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01450774	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02574975	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	09/01/2012	https://clinicaltrials.gov/study/NCT01471340	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01001364	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Withdrawn	11/06/2020	https://clinicaltrials.gov/study/NCT04271839	1	GoF	protect	The trial has been terminated early due to the SARS-CoV-2 pandemic.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01345916	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00252824	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00290264	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	28/05/2014	https://clinicaltrials.gov/study/NCT02062463	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01892787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05322707	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00255255	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00394199	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00651547	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01070888	1	GoF	protect	Unable to reach target goal
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00914654	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Recruiting	22/07/2022	https://clinicaltrials.gov/study/NCT04191434	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01099722	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00734318	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00900874	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	10/01/2019	https://clinicaltrials.gov/study/NCT03788395	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Terminated	23/08/2021	https://clinicaltrials.gov/study/NCT04705727	0.7	GoF	protect	Not enough recruitment in th trial
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb24d6b0-0d69-4a3c-a7f4-a35ca4804657	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02388373	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00327353	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00319306	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00419952	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT03015259	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00242411	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2020	https://clinicaltrials.gov/study/NCT04215848	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00497237	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566149	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00691951	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Recruiting	01/05/2020	https://clinicaltrials.gov/study/NCT04171180	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	04/07/2013	https://clinicaltrials.gov/study/NCT01803555	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00649025	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00238784	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00646321	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00242775	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702325	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00651651	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00244608	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Enrolling by invitation	01/01/2020	https://clinicaltrials.gov/study/NCT04185129	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/09/2008	https://clinicaltrials.gov/study/NCT00867737	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00849095	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	09/12/2005	https://clinicaltrials.gov/study/NCT01089322	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00939341	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00460577	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01570478	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	09/07/2015	https://clinicaltrials.gov/study/NCT02446418	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Terminated	01/05/2013	https://clinicaltrials.gov/study/NCT01845025	1	GoF	protect	Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT01255579	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00862264	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00646009	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00393952	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00393991	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00424008	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00252863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00288379	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00652392	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00235911	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00901368	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00476073	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00383240	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Recruiting	02/06/2017	https://clinicaltrials.gov/study/NCT03387241	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00652002	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00259766	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01511367	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=116464ce-cfd8-4b9f-8b5a-3a114b6ff2b1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00651768	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02345993	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Recruiting	22/07/2022	https://clinicaltrials.gov/study/NCT04191447	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00272753	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00476268	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00130351	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01167010	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00449527	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00646516	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01202084	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Terminated	11/11/2013	https://clinicaltrials.gov/study/NCT01912872	1	GoF	protect	Termination was due to identified errors in data management handling after an internal audit by the sponsor performed by third party.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00381485	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00394121	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00449501	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00646620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00915538	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00646529	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	15/06/2016	https://clinicaltrials.gov/study/NCT02753712	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	09/10/2017	https://clinicaltrials.gov/study/NCT03453112	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00252785	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	13/01/2017	https://clinicaltrials.gov/study/NCT02495168	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	04/03/2014	https://clinicaltrials.gov/study/NCT02045875	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT01676987	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00394368	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02934945	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01404013	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00463866	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00536913	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT01658891	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02725242	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Withdrawn	01/06/2010	https://clinicaltrials.gov/study/NCT00997477	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Terminated	01/09/2006	https://clinicaltrials.gov/study/NCT00385593	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	28/11/2014	https://clinicaltrials.gov/study/NCT02224157	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00419757	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00861926	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02308098	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05831566	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Active, not recruiting	05/10/2022	https://clinicaltrials.gov/study/NCT05292586	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00259792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01475032	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00475813	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01620099	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00862394	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Terminated	31/08/2015	https://clinicaltrials.gov/study/NCT02491970	1	GoF	protect	Difficulty of patients enrollments
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	30/03/2011	https://clinicaltrials.gov/study/NCT01290874	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	07/07/2014	https://clinicaltrials.gov/study/NCT02149199	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00910793	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00646594	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01602523	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00680056	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL	targetBased	4	Withdrawn	01/03/2008	https://clinicaltrials.gov/study/NCT00633776	1	GoF	protect	Sponsor withdrew funding prior to study initiation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	FORMOTEROL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	TERBUTALINE SULFATE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00421122	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a4be57a-a3df-4aa5-be52-845b75e78b3b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94742710-e87e-4e1c-85ee-0a2e7a77f0de	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8265c67f-55bc-40f0-9ede-3e4b4bb178f4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fbf54709-5857-4dbc-9233-ebd7abff88c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=382dcebb-6e41-4335-818d-b5822e3fb884	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=352e3476-2bc4-4995-9fd9-4a8864417f1a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=879be756-991a-42c5-a381-9c8c2ad1fbdb	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed2af9a9-8bc4-4c6a-b8df-e8fc88c93d6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613df3cb-4d55-4d12-ab08-a932481aaa0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7474ef3d-036f-47dd-aea7-be6d1086c0e4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ae8fb3d-9df3-4948-bb07-6e4169521f15	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cec31032-f366-4524-9e01-63146e473b2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	TERBUTALINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a95bc4f-34d3-4b5e-841b-6839e1c1e0c7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d06309-0483-48c6-a9f2-b25dcc31db72	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2b67032-2ad0-4db5-a8b5-f1d3943f65d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fe2669f-ca2a-fd31-e09c-fd2819a8308c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7c031a5-3bf8-4548-8fe7-0c308a45152a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00462540	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95d573-74b2-4b0e-9397-c2cdaf7f41e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bdda27b-e123-4f33-87e2-63f33b2b061e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05f7916c-52f7-4a4f-a19b-f5e35f02fd0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad98bce-bb10-4a04-94e7-d6f55ae60cda	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254422f6-37e0-4dc1-ad3b-b2e20009a7b5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=953ab65b-b157-41b3-8f90-98fa9d7f20c5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5daaf067-49a2-4067-afa4-39411c87524f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d215fe3-1cf6-4bb3-b005-75f1a9d62235	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d92c5d6b-ff10-4087-36a2-1cfc464cb967	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16efdd16-04db-4874-92de-d1de22aee074	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=071e819b-43cd-48f7-b63e-c891936dcfc4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=829f381a-7888-4579-a2c5-4359764813c3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26138eb9-ff04-41cc-94c8-83edcba78b86	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f0d280b-747e-4232-9d4d-a5c964f0daad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1821db2-8a50-40e1-8448-4e59eafd2612	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133fb50a-68d3-4d1b-a47a-67d07cc48da5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e439746-9808-4102-a92f-bf6c3f1e3513	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a56892b-7485-4570-9a1d-53ef23f07cbe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c2fe10-c61f-4cbe-bc45-7ab14baa691c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e701d71-1dcb-4b84-bada-84e4f04f5e62	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bcc115b-88da-4ff0-b4e1-ef10d5287e54	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=708615b8-79b1-4eaa-b765-abb01be3233a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b2ff7e6-d9fb-47ed-85eb-859cb1bc8a79	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77f24a8c-0a9a-4708-a401-3f56b5d4f2c1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecc00500-58b8-491f-80df-dc6c89a08cae	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab1cbed4-50c4-4769-9947-1927333f278c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938ab43d-bf4c-477f-b918-aabe738d562b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=374cbcbb-a37c-4057-b9a9-f70b3fdb803c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8839cf1-ec1c-42e6-a4d3-b089e95337e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=285a656c-f77f-4e77-b0a8-a0e9c901803f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34b6ab14-9ed5-4651-9be6-84685e6aa919	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49edc01-1ea6-4f88-883a-bb4bc2bf4b3f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9d01507-ae72-4322-93d5-5d857b1b2caa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b72742df-1a6b-4483-aff3-3e79db5e015d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e65e8c22-d9d9-4473-8240-cfd154b8e6c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ec64742-5802-49f0-bbbe-95580730c0a7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58860ee1-5a9d-4422-b9bc-78e8b7958b53	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fbbb275-24a8-43c6-b341-baf90957cd69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e7c1e97-b8b2-44c0-aeac-18f9142a522b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c64255e-074c-41f8-a344-3686a0685020	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0d31515-28cf-4041-9007-a5a9b52dc78d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a90911e-adb5-4331-8d1a-f791fba549f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00665600	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	3	Completed	28/09/2017	https://clinicaltrials.gov/study/NCT03256695	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=774b1ef9-015e-4e8e-9c52-d305de1ef85e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4	Completed	02/12/2020	https://clinicaltrials.gov/study/NCT04606394	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f422539-5708-46fd-944d-c88a12fc5ec3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574824f3-51cc-4b94-9c10-e3204d8b19f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53176c67-ebcd-4b07-a08a-f2df3c541af9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acc9a53e-304d-44e4-b4ab-5303d1361118	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c53c391b-de2f-4df8-8c25-6764564580c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c1f3881-2b68-4bdb-a12f-8134fe8ba961	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	atopic asthma	ALBUTEROL SULFATE	targetBased	3	Completed	09/05/2018	https://clinicaltrials.gov/study/NCT03468790	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87b8cd3c-2849-4b50-b63e-9ea379165c07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29f0d08e-14d7-4659-bc00-0d84ae69cb7f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3d2ab1e-8f91-4a4d-aa6b-5a57f59ad56b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0ec9932-b2a3-4776-a7e8-2aeded019da4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74170607-50c0-4de5-847e-64da9b1d52db	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69ffacaa-c7e5-4016-9e77-79f7d724baad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ffb3297-6d69-4475-9bb3-ccecf3ede614	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dee492-8bf9-4360-be9b-9d6ee1ecb256	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f454947c-6055-474b-bf35-29a379e01aa3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dc143e7-6bab-42c8-b3e9-9d604d202e73	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3544356-e36a-4ce6-8235-cb0531c658ad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb952b7-8826-40a1-ac7b-38ec1bd9b94e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afcf38bf-b183-4569-b43f-25deb97f6693	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb4f1002-9372-4fac-aea3-99142f93dd37	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f090fb-c591-4d6a-98b7-925b0bb17c38	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bfd443-1d9d-4806-b044-6ff874b92b25	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a801d6-9573-4997-9b4a-aec6db6459ed	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911f605d-5451-49e2-a484-00f619f2012b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23c05e9a-9df5-4978-8831-cf562aa4ba92	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9b20e4-82e6-4151-9c9d-39aaf2a767e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a1cb095-c3c6-4629-9a88-aeae949541ef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d6ba1a-1599-48a3-8dbd-a8b06af20fe1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22367ff1-5edf-429a-955a-728e42695f60	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5329614f-ae0b-4854-bb6f-ea0b7dae87c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcc9dbb-5758-4979-b84b-891f3d04f61e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae35ec1f-526a-49bf-8262-c50e40190d1f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f248b57a-2c06-4ed8-817e-e6ff42f5ce88	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecc00500-58b8-491f-80df-dc6c89a08cae	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a1cb095-c3c6-4629-9a88-aeae949541ef	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e439746-9808-4102-a92f-bf6c3f1e3513	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00646620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b2ff7e6-d9fb-47ed-85eb-859cb1bc8a79	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acc9a53e-304d-44e4-b4ab-5303d1361118	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05f7916c-52f7-4a4f-a19b-f5e35f02fd0b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4	Active, not recruiting	09/07/2021	https://clinicaltrials.gov/study/NCT04997304	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b49edc01-1ea6-4f88-883a-bb4bc2bf4b3f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a56892b-7485-4570-9a1d-53ef23f07cbe	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=071e819b-43cd-48f7-b63e-c891936dcfc4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a7c031a5-3bf8-4548-8fe7-0c308a45152a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a90911e-adb5-4331-8d1a-f791fba549f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02584257	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00577655	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16efdd16-04db-4874-92de-d1de22aee074	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22367ff1-5edf-429a-955a-728e42695f60	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb952b7-8826-40a1-ac7b-38ec1bd9b94e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00144846	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c1f3881-2b68-4bdb-a12f-8134fe8ba961	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c64255e-074c-41f8-a344-3686a0685020	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5daaf067-49a2-4067-afa4-39411c87524f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574824f3-51cc-4b94-9c10-e3204d8b19f8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=911f605d-5451-49e2-a484-00f619f2012b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bdda27b-e123-4f33-87e2-63f33b2b061e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02126839	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=374cbcbb-a37c-4057-b9a9-f70b3fdb803c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34b6ab14-9ed5-4651-9be6-84685e6aa919	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5329614f-ae0b-4854-bb6f-ea0b7dae87c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ffb3297-6d69-4475-9bb3-ccecf3ede614	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Not yet recruiting	11/12/2023	https://clinicaltrials.gov/study/NCT06154304	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77f24a8c-0a9a-4708-a401-3f56b5d4f2c1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa5ebedb-069c-4a1e-9a25-b6fa957e6c2b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1821db2-8a50-40e1-8448-4e59eafd2612	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=953ab65b-b157-41b3-8f90-98fa9d7f20c5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8e701d71-1dcb-4b84-bada-84e4f04f5e62	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e7c1e97-b8b2-44c0-aeac-18f9142a522b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f454947c-6055-474b-bf35-29a379e01aa3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9d01507-ae72-4322-93d5-5d857b1b2caa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae35ec1f-526a-49bf-8262-c50e40190d1f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53176c67-ebcd-4b07-a08a-f2df3c541af9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00861926	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	22/09/2018	https://clinicaltrials.gov/study/NCT03528577	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=becf2107-bbc9-4b7b-87a5-3221ff6fc5cf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6afb1ec5-6771-4ce7-accb-fdff05ebf3b9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b72742df-1a6b-4483-aff3-3e79db5e015d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23c05e9a-9df5-4978-8831-cf562aa4ba92	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad98bce-bb10-4a04-94e7-d6f55ae60cda	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fbbb275-24a8-43c6-b341-baf90957cd69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbcc9dbb-5758-4979-b84b-891f3d04f61e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f0d280b-747e-4232-9d4d-a5c964f0daad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2b67032-2ad0-4db5-a8b5-f1d3943f65d8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=285a656c-f77f-4e77-b0a8-a0e9c901803f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e65e8c22-d9d9-4473-8240-cfd154b8e6c8	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Withdrawn	01/04/2022	https://clinicaltrials.gov/study/NCT05292976	0.7	GoF	protect	Business reasons
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=774b1ef9-015e-4e8e-9c52-d305de1ef85e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	20/03/2019	https://clinicaltrials.gov/study/NCT03847896	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4	Completed	27/07/2020	https://clinicaltrials.gov/study/NCT04159519	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69ffacaa-c7e5-4016-9e77-79f7d724baad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=133fb50a-68d3-4d1b-a47a-67d07cc48da5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58860ee1-5a9d-4422-b9bc-78e8b7958b53	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=708615b8-79b1-4eaa-b765-abb01be3233a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95d573-74b2-4b0e-9397-c2cdaf7f41e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26138eb9-ff04-41cc-94c8-83edcba78b86	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=938ab43d-bf4c-477f-b918-aabe738d562b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f248b57a-2c06-4ed8-817e-e6ff42f5ce88	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00634829	0.7	GoF	protect	IND voluntarily withdrawn, without prejudice
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3d2ab1e-8f91-4a4d-aa6b-5a57f59ad56b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4	Completed	01/05/1998	https://clinicaltrials.gov/study/NCT02182713	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12d06309-0483-48c6-a9f2-b25dcc31db72	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00634517	0.7	GoF	protect	IND voluntarily withdrawn, without prejudice
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d215fe3-1cf6-4bb3-b005-75f1a9d62235	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dc143e7-6bab-42c8-b3e9-9d604d202e73	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	13/02/2017	https://clinicaltrials.gov/study/NCT02969408	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87b8cd3c-2849-4b50-b63e-9ea379165c07	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74170607-50c0-4de5-847e-64da9b1d52db	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205636s004lbl.pdf	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bfd443-1d9d-4806-b044-6ff874b92b25	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dee492-8bf9-4360-be9b-9d6ee1ecb256	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fe2669f-ca2a-fd31-e09c-fd2819a8308c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a801d6-9573-4997-9b4a-aec6db6459ed	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99d6ba1a-1599-48a3-8dbd-a8b06af20fe1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=829f381a-7888-4579-a2c5-4359764813c3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=254422f6-37e0-4dc1-ad3b-b2e20009a7b5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0ec9932-b2a3-4776-a7e8-2aeded019da4	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bcc115b-88da-4ff0-b4e1-ef10d5287e54	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4a92e7c-6d19-45e7-91f0-685f68383784	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04207840	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3544356-e36a-4ce6-8235-cb0531c658ad	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb4f1002-9372-4fac-aea3-99142f93dd37	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c53c391b-de2f-4df8-8c25-6764564580c0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c2fe10-c61f-4cbe-bc45-7ab14baa691c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8f090fb-c591-4d6a-98b7-925b0bb17c38	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f422539-5708-46fd-944d-c88a12fc5ec3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab1cbed4-50c4-4769-9947-1927333f278c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	13/12/2018	https://clinicaltrials.gov/study/NCT03769090	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0d31515-28cf-4041-9007-a5a9b52dc78d	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29f0d08e-14d7-4659-bc00-0d84ae69cb7f	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8839cf1-ec1c-42e6-a4d3-b089e95337e5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00394329	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9b20e4-82e6-4151-9c9d-39aaf2a767e2	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afcf38bf-b183-4569-b43f-25deb97f6693	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Recruiting	30/03/2023	https://clinicaltrials.gov/study/NCT05884970	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4	Completed	11/11/2021	https://clinicaltrials.gov/study/NCT05084222	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d92c5d6b-ff10-4087-36a2-1cfc464cb967	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ec64742-5802-49f0-bbbe-95580730c0a7	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	ALBUTEROL SULFATE	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00667407	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73b55902-273a-4734-8deb-af6eb68b5523	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46633af4-98c1-471f-9232-d719c6d8e445	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4a4021c-c092-41bf-91ed-ef483fd52732	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	METAPROTERENOL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43ff5156-e08b-4dc4-93a6-8c727676daa1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	METAPROTERENOL SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf566e38-f6ff-4b86-9537-8684943b36eb	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	asthma	ALFACALCIDOL	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02747381	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	INDACATEROL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL MALEATE	targetBased	4	Completed	27/08/2014	https://clinicaltrials.gov/study/NCT02202616	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL MALEATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL MALEATE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01437748	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	INDACATEROL MALEATE	targetBased	4	Completed	14/02/2014	https://clinicaltrials.gov/study/NCT01985334	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	INDACATEROL MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL TARTRATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	ARFORMOTEROL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	4	Terminated	01/11/2014	https://clinicaltrials.gov/study/NCT02275481	1	GoF	protect	lack of enrollment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00685841	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00571428	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	4	Terminated	03/10/2017	https://clinicaltrials.gov/study/NCT03219866	1	GoF	protect	Lower enrollment than Sponsor expected - Sponsor stopped study
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00754546	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	ARFORMOTEROL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL TARTRATE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL TARTRATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00064402	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	ARFORMOTEROL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bronchitis	ARFORMOTEROL TARTRATE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00250679	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	chronic bronchitis	IVACAFTOR	targetBased	4	Withdrawn	01/01/2020	https://clinicaltrials.gov/study/NCT03251911	1	GoF	protect	no participants enrolled
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	chronic bronchitis	IVACAFTOR	targetBased	4	Withdrawn	01/01/2020	https://clinicaltrials.gov/study/NCT03251911	1	GoF	protect	no participants enrolled
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	respiratory system disease	IVACAFTOR	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R07AX02	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	respiratory system disease	IVACAFTOR	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=R07AX02	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01117012	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01117012	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01705145	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01705145	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02347657	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02347657	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Terminated	01/10/2018	https://clinicaltrials.gov/study/NCT03956589	0.5	GoF	protect	Patient inclusion has stopped after interim analysis.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Terminated	01/10/2018	https://clinicaltrials.gov/study/NCT03956589	0.5	GoF	protect	Patient inclusion has stopped after interim analysis.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01807923	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01807923	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT01937325	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT01937325	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01807949	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01807949	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	16/08/2017	https://clinicaltrials.gov/study/NCT03277196	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	16/08/2017	https://clinicaltrials.gov/study/NCT03277196	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	24/02/2020	https://clinicaltrials.gov/study/NCT04235140	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	24/02/2020	https://clinicaltrials.gov/study/NCT04235140	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	17/05/2018	https://clinicaltrials.gov/study/NCT03559062	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	17/05/2018	https://clinicaltrials.gov/study/NCT03559062	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	02/06/2016	https://clinicaltrials.gov/study/NCT02725567	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	02/06/2016	https://clinicaltrials.gov/study/NCT02725567	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01614470	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01614470	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	28/08/2019	https://clinicaltrials.gov/study/NCT04058353	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	28/08/2019	https://clinicaltrials.gov/study/NCT04058353	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	18/07/2017	https://clinicaltrials.gov/study/NCT03068312	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	18/07/2017	https://clinicaltrials.gov/study/NCT03068312	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02412111	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02412111	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02953314	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02953314	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01614457	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01614457	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fc1c40e-cfac-47a1-9e1a-61ead3570600	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fc1c40e-cfac-47a1-9e1a-61ead3570600	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02392234	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02392234	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01946412	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01946412	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302ae804-37db-44fd-ac2f-3dbdeda9aa4b	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=302ae804-37db-44fd-ac2f-3dbdeda9aa4b	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02544451	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02544451	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	07/09/2018	https://clinicaltrials.gov/study/NCT03601637	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	07/09/2018	https://clinicaltrials.gov/study/NCT03601637	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02565914	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02565914	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05422222	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05422222	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02516410	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02516410	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00909727	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00909727	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	08/11/2022	https://clinicaltrials.gov/study/NCT05444257	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Active, not recruiting	08/11/2022	https://clinicaltrials.gov/study/NCT05444257	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03537651	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03537651	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01707290	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01707290	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	19/06/2020	https://clinicaltrials.gov/study/NCT04353817	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	19/06/2020	https://clinicaltrials.gov/study/NCT04353817	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02514473	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02514473	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02934698	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02934698	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931839	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931839	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02742519	0.7	GoF	protect	Low enrollment.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02742519	0.7	GoF	protect	Low enrollment.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	03/10/2019	https://clinicaltrials.gov/study/NCT04105972	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	03/10/2019	https://clinicaltrials.gov/study/NCT04105972	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	12/05/2017	https://clinicaltrials.gov/study/NCT03125395	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	12/05/2017	https://clinicaltrials.gov/study/NCT03125395	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01897233	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01897233	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	24/05/2017	https://clinicaltrials.gov/study/NCT03150719	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	24/05/2017	https://clinicaltrials.gov/study/NCT03150719	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00909532	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	IVACAFTOR	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00909532	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	MORPHINE SULFATE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01236495	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	lung disease	MORPHINE SULFATE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01236495	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02514473	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02514473	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	4	Terminated	01/10/2018	https://clinicaltrials.gov/study/NCT03956589	0.5	GoF	protect	Patient inclusion has stopped after interim analysis.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	4	Terminated	01/10/2018	https://clinicaltrials.gov/study/NCT03956589	0.5	GoF	protect	Patient inclusion has stopped after interim analysis.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01807949	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01807949	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fc1c40e-cfac-47a1-9e1a-61ead3570600	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3fc1c40e-cfac-47a1-9e1a-61ead3570600	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01897233	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01897233	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01807923	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01807923	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02544451	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02544451	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	24/02/2020	https://clinicaltrials.gov/study/NCT04235140	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	24/02/2020	https://clinicaltrials.gov/study/NCT04235140	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	12/05/2017	https://clinicaltrials.gov/study/NCT03125395	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	12/05/2017	https://clinicaltrials.gov/study/NCT03125395	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931839	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	LUMACAFTOR	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931839	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	OLODATEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01e15aee-40e0-23f3-537f-c96dd63e2cb1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	OLODATEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	OLODATEROL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Nasal congestion	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=750f9a39-acdc-4abc-800e-467884a4dcea	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=172e970d-6773-4796-a280-3370e2f46c69	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2170f081-c03f-47e8-bc63-4052c5e653fa	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	common cold	EPHEDRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1239e824-aa60-4b7f-9910-81f96ebe6c70	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02565914	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02565914	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03537651	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	25/04/2018	https://clinicaltrials.gov/study/NCT03537651	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	19/06/2020	https://clinicaltrials.gov/study/NCT04353817	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	19/06/2020	https://clinicaltrials.gov/study/NCT04353817	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	24/05/2017	https://clinicaltrials.gov/study/NCT03150719	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	24/05/2017	https://clinicaltrials.gov/study/NCT03150719	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02412111	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02412111	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02392234	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02392234	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02953314	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02953314	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05422222	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Recruiting	21/06/2022	https://clinicaltrials.gov/study/NCT05422222	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02347657	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/01/2015	https://clinicaltrials.gov/study/NCT02347657	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	28/08/2019	https://clinicaltrials.gov/study/NCT04058353	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	28/08/2019	https://clinicaltrials.gov/study/NCT04058353	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	03/10/2019	https://clinicaltrials.gov/study/NCT04105972	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	03/10/2019	https://clinicaltrials.gov/study/NCT04105972	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	17/05/2018	https://clinicaltrials.gov/study/NCT03559062	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	17/05/2018	https://clinicaltrials.gov/study/NCT03559062	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02516410	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02516410	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	08/11/2022	https://clinicaltrials.gov/study/NCT05444257	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Active, not recruiting	08/11/2022	https://clinicaltrials.gov/study/NCT05444257	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	TEZACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pulmonary arterial hypertension	AV-101	targetBased	3	Active, not recruiting	02/11/2022	https://clinicaltrials.gov/study/NCT05557942	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	chronic obstructive pulmonary disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	lung disease	DOXAPRAM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Apnea	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	lung disease	DOXAPRAM HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=954859c0-a121-34d6-e053-2a95a90a1e19	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	hypoxia	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02171910	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Apnea	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00389909	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	hypoxia	DOXAPRAM HYDROCHLORIDE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02171910	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL TARTRATE	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00073827	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL TARTRATE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00064389	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL TARTRATE	targetBased	3	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02150499	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	LEVALBUTEROL TARTRATE	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00073814	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL FUMARATE	targetBased	4	Withdrawn	01/03/2008	https://clinicaltrials.gov/study/NCT00633776	1	GoF	protect	Sponsor withdrew funding prior to study initiation
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic bronchitis	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	25/05/2021	https://clinicaltrials.gov/study/NCT04876677	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01462942	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00215436	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00932646	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01488019	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Recruiting	24/10/2023	https://clinicaltrials.gov/study/NCT06067828	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT01853787	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Not yet recruiting	15/02/2021	https://clinicaltrials.gov/study/NCT04737655	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00308191	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb24d6b0-0d69-4a3c-a7f4-a35ca4804657	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Withdrawn	04/10/2021	https://clinicaltrials.gov/study/NCT04671355	1	GoF	protect	Continuing delays due to COVID-19 pandemic
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Recruiting	07/07/2017	https://clinicaltrials.gov/study/NCT03275116	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00139932	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	05/07/2016	https://clinicaltrials.gov/study/NCT02796677	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00507234	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Withdrawn	04/12/2017	https://clinicaltrials.gov/study/NCT03181880	1	GoF	protect	Study stopped early as AZ have re-prioritised to focus on research to help bring existing and innovative medicines to more patients with asthma and COPD.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Recruiting	29/02/2024	https://clinicaltrials.gov/study/NCT06282861	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02467452	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02497001	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	09/08/2016	https://clinicaltrials.gov/study/NCT03262012	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02268396	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00931385	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Completed	25/08/2015	https://clinicaltrials.gov/study/NCT02533505	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01970878	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01911364	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	14/12/2016	https://clinicaltrials.gov/study/NCT03197818	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01946620	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Withdrawn	19/01/2024	https://clinicaltrials.gov/study/NCT05970263	1	GoF	protect	Recruitment challenges
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01854658	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01245569	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	30/03/2015	https://clinicaltrials.gov/study/NCT02343458	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01908140	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01437397	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Recruiting	28/04/2022	https://clinicaltrials.gov/study/NCT04320342	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01204034	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01572792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Recruiting	21/02/2024	https://clinicaltrials.gov/study/NCT06283966	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	24/01/2017	https://clinicaltrials.gov/study/NCT03022097	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02972476	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Terminated	01/09/2011	https://clinicaltrials.gov/study/NCT01351792	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT02937584	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	20/11/2017	https://clinicaltrials.gov/study/NCT03268226	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00215449	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03162055	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	19/09/2011	https://clinicaltrials.gov/study/NCT01437540	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01854645	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00280371	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	chronic obstructive pulmonary disease	FORMOTEROL FUMARATE	targetBased	3	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00929851	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01475032	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2020	https://clinicaltrials.gov/study/NCT04215848	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05322707	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00383552	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00413387	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Unknown status	01/02/2012	https://clinicaltrials.gov/study/NCT01404013	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05831566	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	28/05/2014	https://clinicaltrials.gov/study/NCT02062463	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=116464ce-cfd8-4b9f-8b5a-3a114b6ff2b1	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01345916	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Withdrawn	01/02/2014	https://clinicaltrials.gov/study/NCT01658891	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00915538	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01001364	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00475813	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Unknown status	01/09/2008	https://clinicaltrials.gov/study/NCT00867737	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01566149	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01450774	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702325	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb24d6b0-0d69-4a3c-a7f4-a35ca4804657	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	13/01/2017	https://clinicaltrials.gov/study/NCT02495168	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	10/01/2019	https://clinicaltrials.gov/study/NCT03788395	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Enrolling by invitation	01/01/2020	https://clinicaltrials.gov/study/NCT04185129	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	09/12/2005	https://clinicaltrials.gov/study/NCT01089322	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Active, not recruiting	05/10/2022	https://clinicaltrials.gov/study/NCT05292586	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00862394	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae02436e-9528-490e-a844-0c0f6f2843f9	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00910793	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01167010	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00252863	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00476073	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00394199	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00649025	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00393952	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00747318	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00563056	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00901368	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01570478	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00394368	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	29/12/2016	https://clinicaltrials.gov/study/NCT03015259	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01511367	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=715433dc-cb2b-43ea-b6df-c5b4177adc6c	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	09/07/2015	https://clinicaltrials.gov/study/NCT02446418	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01202084	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01620099	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00383240	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00393991	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	09/10/2017	https://clinicaltrials.gov/study/NCT03453112	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01099722	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	4	Completed	04/03/2014	https://clinicaltrials.gov/study/NCT02045875	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00394121	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	asthma	FORMOTEROL FUMARATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00734318	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04212000-ec03-42a3-8b9e-3a28237f415e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fafa4cf1-99c2-43d5-73ad-51f256de3be0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb2fe258-fe2e-47f6-8adf-ca75bf6f90af	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	emphysema	FORMOTEROL FUMARATE	targetBased	4	Withdrawn	01/03/2008	https://clinicaltrials.gov/study/NCT00633776	1	GoF	protect	Sponsor withdrew funding prior to study initiation
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic obstructive pulmonary disease	LIRAGLUTIDE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03466021	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic obstructive pulmonary disease	LIRAGLUTIDE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03466021	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	chronic obstructive pulmonary disease	LIRAGLUTIDE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03466021	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Completed	07/03/2018	https://clinicaltrials.gov/study/NCT03447249	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Terminated	03/08/2018	https://clinicaltrials.gov/study/NCT03633526	0.7	GoF	protect	Study discontinued after Part A due to Sponsor's discretion.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Terminated	13/07/2018	https://clinicaltrials.gov/study/NCT03447262	0.7	GoF	protect	At Sponsor's Discretion
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	BAMOCAFTOR	targetBased	3	Completed	01/05/2018	https://clinicaltrials.gov/study/NCT03460990	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Not yet recruiting	01/10/2024	https://clinicaltrials.gov/study/NCT06460506	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/08/2019	https://clinicaltrials.gov/study/NCT04043806	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	27/10/2021	https://clinicaltrials.gov/study/NCT05076149	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	19/11/2020	https://clinicaltrials.gov/study/NCT04537793	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Active, not recruiting	17/01/2022	https://clinicaltrials.gov/study/NCT05153317	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	14/01/2022	https://clinicaltrials.gov/study/NCT05111145	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	05/12/2019	https://clinicaltrials.gov/study/NCT04058366	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	03/08/2018	https://clinicaltrials.gov/study/NCT03525548	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/10/2018	https://clinicaltrials.gov/study/NCT03525574	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	09/05/2022	https://clinicaltrials.gov/study/NCT05274269	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Recruiting	27/06/2023	https://clinicaltrials.gov/study/NCT05882357	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03691779	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	4	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT03624101	1	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03525444	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	04/05/2020	https://clinicaltrials.gov/study/NCT04362761	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04599465	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Active, not recruiting	23/11/2022	https://clinicaltrials.gov/study/NCT05331183	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	11/01/2021	https://clinicaltrials.gov/study/NCT04545515	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	17/02/2020	https://clinicaltrials.gov/study/NCT04183790	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Enrolling by invitation	11/08/2023	https://clinicaltrials.gov/study/NCT05844449	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	14/09/2021	https://clinicaltrials.gov/study/NCT05033080	0.7	GoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	cystic fibrosis	ELEXACAFTOR	targetBased	3	Completed	12/10/2021	https://clinicaltrials.gov/study/NCT04969224	0.7	GoF	protect
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	Interleukin-1 receptor-like 1	chronic obstructive pulmonary disease	ASTEGOLIMAB	targetBased	3	Recruiting	28/06/2023	https://clinicaltrials.gov/study/NCT05878769	0.7	LoF	protect
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	IL1RL1	Interleukin-1 receptor-like 1	chronic obstructive pulmonary disease	ASTEGOLIMAB	targetBased	3	Recruiting	29/12/2022	https://clinicaltrials.gov/study/NCT05595642	0.7	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.